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Tocopherols and tocotrienols all possess to varying levels the vitamin E 
activity of α-tocopherol, the most bioactive form of the vitamin in vivo.   α-
Tocopherol is the most abundant vitamer in vivo, potentially explaining its higher 
bioactivity.  This is despite higher dietary levels of other vitamers.  The preferential 
retention of α-tocopherol appears to be at the level of elimination.  Urinary 
metabolites of tocopherols, with the phytyl tail truncated to a three-carbon 
carboxylated moiety, were reported previously.  The goal of this work was to elucidate 
the pathway(s) by which these metabolites are formed.  Incubations of tocopherols in 
hepatocyte culture produced all expected intermediates in the predicted pathway of 
catabolism of vitamin E.  This pathway involves ω-hydroxylation of a terminal methyl 
group of the phytyl tail, followed by step-wise removal of two or three carbon units by 
a  β-oxidation mechanism.  Analysis of microsomal enzyme activity led to the 
elucidation of CYP4F2 as the major P450 involved in the initial ω-hydroxylation 
reaction.  Substrate-specificity of this enzyme was high, with activity toward γ-
tocopherol being 10-fold greater than toward α-tocopherol.  Sesamin, known to raise 
plasma  γ-tocopherol to levels near those of α-tocopherol in vivo, was a potent  
 
inhibitor of this enzyme.  Together, these data supported the hypothesis that the ω-
oxidation pathway is an important regulator of vitamin E status.   
Kinetic analyses revealed key features of the tocopherol molecule which 
govern the affinity and activity of the enzyme toward its substrates.  These studies also 
revealed an allosteric nature of CYP4F2.  The finding that α-tocopherol is a positive 
effector of γ-tocopherol metabolism may explain why supplementation with α-
tocopherol decreases plasma concentrations of non-α-tocopherols.   
Tocotrienols differed from tocopherols in their effects on lateral and rotational 
mobility of the microsomal membrane components, and inhibited the activity of 
membrane-bound P450 enzymes, possibly through inhibition of interaction of 
components of the cytochrome P450 multi-enzyme complex.  These effects may play 
a role in the cytotoxic nature of the tocotrienols and highlight the importance of the 
tocopherol-ω-oxidation pathway in minimizing their concentration in biomembranes.  
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Vitamin E History 
The dietary substance termed vitamin E was discovered in 1922 as a 
component of the lipid-soluble fraction of the diet which prevented fetal death and 
resorption in the rat (1).  Several years later work by Olcott and Mattill demonstrated 
the newly discovered vitamin possessed antioxidant activity, although the potency of 
this activity was not always well correlated with the vitamin activity (2).  The structure 
of the vitamin was discovered over the course of several years as it was realized that 
the vitamin was actually a group of molecules possessing the same generic structure 
but differing in vitamin potency based on minor variations in their molecular structure.  
Work by Evans et al demonstrated the vitamin extract from wheat germ contained 
three different molecules, each possessing an alcohol moiety, but with the molecule 
designated “α” much more potent than the “γ” or “β” molecules in the vitamin activity 
assays (2,3).  Meanwhile, Fernholz proposed the full structure of the vitamin after 
identifying the presence of a hydroquinone and phytyl tail within the vitamin structure 
(4).  The structure was designated “tocopherol” by Evans and GM Calhoun to 
designate its function in childbirth (greek “tokos-pherein”) and its alcohol structure (-
ol).  One more tocopherol, designated “δ” was isolated from soybean oil (5).  Years 
later, the tocotrienols were discovered in wheat germ oil and bran as the unsaturated 
counterparts of the tocopherols (6).  As with the tocopherols, the tocotrienols too 
possess vitamin E activity, and as such the term “vitamin E” designates both the 
tocotrienols and tocopherols.  Thus, it is erroneous to use this term synonymously with 
only α-TOH. 
Vitamin E Structure 
The generic structure of vitamin E is now known to be made up of a 
heterocyclic chromanol ring substituted at the 2-carbon with a phytyl tail (Figure 1.1).   
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Figure 1.1 
Vitamin E structure depicting variations in vitamer structural features. 
   R1 R2 R3 
Tri-methyl  α  CH3 CH3 CH3 
Di-methyl  γ  H  CH3 CH3 
Di-methyl  β  CH3  H  CH3 
Di-methyl  ε  CH3 CH3  H 
Mono-methyl  δ  H H  CH3 
No-methyl  tocol  H H H 
Chromanol Ring  Phytyl Tail 
Tocopherol = no double bonds on phytyl tail 
All rac = racemization at carbons 2, 4’, and 8’ 
Tocotrienol = double bonds at carbons 3’, 7’, and 11’  
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The greek letter designations α-,  γ-,  β-, and δ- indicate tri-, di-, di-, and mono-
methylation variations respectively around the phenol moiety of the chromanol ring at 
carbons 5, 7, and 8 for both the tocopherols and tocotrienols.  The unsaturated 
tocotrienols possess three unconjugated double bonds at the 3’, 7’, and 11’ carbons of 
the phytyl tail.  The chiral carbons of the phytyl tail at the 2, 4’ and 8’ positions exist 
in the synthetic forms of the vitamin in both the R or S positions, resulting in eight 
potential stereoisomers of the all racemic (all-rac) vitamin E.  The hydroxyl group on 
the chromanol ring may be synthetically esterified with substituents such as an acetate 
or succinate moiety.   
Activity as a Vitamin 
  As mentioned, the various vitamers of vitamin E differ in their vitamin E 
activity based on a variety of activity assays.  Over the years since the first 
identification of vitamin E activity there has been much debate as to the true vitamin 
function of E and therefore the best assays to measure deficiency and to compare the 
activities of the vitamers.  The original rat fetal resorption assay continues to be the 
most commonly accepted measure of vitamin activity, although several other methods 
exist, including prevention of red blood cell hemolysis in the rat, myopathy prevention 
in the chick, and myopathy cure in the rat.  Official bioactivity data for vitamin E are 
currently based on the rat fetal resorption assay.  By this assay, 1 mg all-rac-α-
tocopherol acetate is defined to be equal to 1 international unit (IU) or 1 US 
Pharmacopeia unit (USP) to which all other vitamers are compared.  Accordingly, the 
natural RRR-α-tocopherol possesses 1.36 times the activity of the standard and is the 
most bioactive of the vitamers.  The bioactivity values of each of the vitamers are 
shown in Table 1.1 (7).   Current Daily Recommended Intake guidelines ignore the 
non-α forms of the vitamin and are based only on α-tocopherol intake (8).  The 
quantitative human requirements are based largely on data from studies using the ex  
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Table 1.1 
Bioactivity of the vitamin E vitamers as determined by the rat fetal resorption assay 
(Beiri and Mckenna, 1981).  One α-TOH equivalent is equal to the activity of 1 mg α-
TOH and the activity of 1 mg of each of the other vitamers is determined by 
comparison with 1 mg α-TOH. 
 
 
 
 
 
 
Vitamer (1 mg)  α-TOH equivalents 
α-TOH 1.0 
all rac-α-TOH 0.74 
γ-TOH 0.1 
β-TOH 0.5 
δ-TOH 0.03 
α-T3 0.3 
β-T3 0.05 
γ-T3 n.d. 
δ-T3 n.d.  
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vivo hydrogen peroxide-induced erythrocyte lysis (9-14).  From these data, a plasma 
concentration of 12µM was chosen as adequate (Estimated Adequate Requirement, 
EAR) to prevent in vitro hydrogen peroxide-induced hemolysis, by which the 
NHANES III study indicates greater than 95% of the US population is not vitamin E 
deficient (15).  By vitamin E repletion studies (9) this plasma level can be achieved in 
adults by an intake of 12 mg/day α-tocopherol.  Based on an RDA of 120% the EAR, 
the current Recommended Daily Allowance of vitamin E is set at 15 mg/day of α-
tocopherol (8).  There is little evidence of toxicity of supplemental doses of α-
tocopherol at levels as high as 2,100 mg/day. 
Vitamin E function 
While there are several measures of vitamin E deficiency, no one molecular 
function has been clearly identified as responsible for deficiency symptoms.   The 
most well accepted function of vitamin E is as an antioxidant in lipid membranes that 
prevents the propagation of free-radical reactions, especially in the context of 
polyunsaturated fatty acids (PUFAs) found in membranes and lipoproteins (16,17).  
The vitamin E molecule is able to donate an electron to a peroxyl radical, effectively 
quenching the free radical chain according to the following scenario where RH 
indicates a PUFA, ROO* indicates a peroxyl radical, and VitE-O* indicates a 
tocopheroxyl radical (18): 
(1) ROO* + R’H Æ ROOH + R’* 
(2) R’* + O2 Æ R’OO* …and so on… 
In the presence of vitamin E the reaction becomes: 
(1) R1OO* + R2H + VitE-OHÆ R1OOH +  R2H + VitE-O* 
This radical-quenching reaction is made favorable by the fact that the peroxyl 
radical reacts with the vitamin E molecule several orders of magnitude faster than with 
another PUFA (19).  Once the tocopheroxyl radical has been generated, it can  
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potentially act as a prooxidant to oxidize other lipids; however, other fates may be 
more favorable, including recycling back to the tocopherol molecule by other 
antioxidants or further oxidation to the stable tocopherol quinone.   
While vitamin E is an extremely potent antioxidant, this capability does not 
explain the various biopotencies noted among the vitamers.  Chemical analysis of the 
antioxidant activity in vivo of the tocopherols and tocotrienols reveals all have similar 
antioxidant activity to the most biopotent vitamer, α-tocopherol (20).  Some reports 
have even demonstrated a greater antioxidant effect of tocotrienols when examined in 
lipid membranes (21).  Clearly, the bioactivity differences among the vitamers 
observed in vivo are not due to differences in radical-trapping ability.   
  In recent years numerous non-antioxidant functions have been discovered for 
vitamin E, many of which are specific to certain vitamers.  α-Tocopherol has been 
shown to function as an inhibitor of protein kinase C and smooth muscle cell 
proliferation (22,23), 5-lipoxygenase ((24), and phospholipase A2 (25).  It has also 
been demonstrated to activate protein phosphatase 2A and diacylglycerol kinase (26), 
to be a regulator of gene expression of numerous proteins including scavenger 
receptors (27), α-tropomyosin (28), and α-tocopherol transfer protein (29,30), and an 
inhibitor of platelet aggregation (31), and monocyte adhesion (32).  γ-Tocopherol, 
lacking a methyl group at the carbon 5 position is able to scavenge peroxynitrite 
radicals at this nucleophilic position (33).  This effect is not seen for α-tocopherol 
which is methylated at carbon 5.  Brillant et al. have demonstrated that inhibition of 
O2
- production by THP-1 promonocytes is essentially limited to δ-tocopherol (34).  γ-
Tocopherol is additionally a much greater inhibitor of PGE2 mediated inflammatory 
response than α-tocopherol (35).  Urinary metabolites of γ-TOH show this same anti-
inflammatory effect and were originally discovered as natriuretic factors (36).  Several 
studies have indicated a role for γ-TOH in the inhibition of prostate and colon cancer  
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cell growth (37-39).  The tocotrienols regulate the expression of HMG-CoA Reductase 
by increasing the degradation rate of the reductase, thereby decreasing cholesterol 
synthesis (40).  The tocotrienols induce apoptosis and inhibit proliferation in a wide 
variety of human and murine cell types (41-44).  They also are more effective than the 
tocopherols in reducing endothelial adhesion to monocytes by reducing expression of 
adhesion molecules (45) and in preventing glutamate-induced neuronal cell death (46).  
Despite this wide variety of vitamin E activities, no activity has been clearly 
elucidated as the one giving the tocopherols or tocotrienols their vitamer function.  
Still, it is clear that there are numerous potential beneficial effects of all the vitamers 
beyond that of α-tocopherol. 
Sources of Vitamin E and average intake 
  As vitamin E are lipid soluble substances synthesized only by plants, its main 
source is from plant oils.  While all the tocopherols and tocotrienols are found at 
various levels in the plant seed, the leaves and other chloroplast-rich parts of the plant 
predominantly contain α-tocopherol.  The distribution of the vitamers in plant oils can 
vary substantially, depending on the plant from which the oil is derived (Figure 1.2).  
In many cases, α-tocopherol is only a minor vitamer found in the oil.  Animal sources 
of vitamin E in the diet are derived wholly from feeds as no animals can synthesize the 
tocochromanol molecule.  However, the vitamer composition of all animal-derived 
food products is >90% α-tocopherol (47).   
Reports on average intakes of vitamin E vary greatly due to the difficulty in 
obtaining accurate food intake data.  The intake of α-tocopherol has been estimated 
between 4 and 13 mg/day (48).  Given the main sources of dietary lipids in the U.S. 
diet being soy and corn oils, the average intake of γ-tocopherol is about 2.5 times that 
of α-tocopherol (49).  Very little data is available concerning the average daily intake 
of the other vitamers.  Dietary supplemental forms of vitamin E are mainly limited to  
 
 
9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 
Distribution of vitamin E vitamers in plant oils (mg/100g oil).  Tocotrienols were not 
analyzed in corn oil.  γ- and δ-T3 were not analyzed in wheat germ. 
(Data taken from Dial and Eitenmiller, 1995; Sheppard et al, 1993; Ong, 1993) 
α-tocopherol, with a large proportion of the supplements consisting of synthetic, and 
therefore all-racemic, α-tocopherol rather than the natural RRR form.   
Soybean
Corn
Olive
Coconut
Wheat germ
Palm
0 50 100 150 200 250 300
Vitamer content (mg/100g)
 α-TOH
 γ-TOH
 β-TOH
 δ-TOH
 α-T3
 γ-T3
 β-T3
 δ-T3
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Vitamin E Plasma and Tissue Concentrations 
Despite the predominance of γ-tocopherol in the diet over α-tocopherol, data 
of plasma and tissue tocopherol concentrations reveal that the relative ratios of the 
vitamin E vitamers in the body do not reflect those in the diet.  Table 1.2 shows the 
relative concentrations of tocopherols in the plasma and tissues, demonstrating α-
tocopherol plasma concentrations are greater than 10 times the concentration of the 
other vitamers (50,51).  
The concentration of α-tocopherol in tissues is also greater than that of the 
other vitamers, although the ratio of α-TOH:γ-TOH in adipose tissue is reported to be 
half that in plasma, suggesting the tissues are more enriched in the other vitamers (or 
more depleted of α-tocopherol) compared to plasma (52).  In fact, there are reports of 
near equal, or higher levels of γ-tocopherol in the skin and muscle when compared 
with α-tocopherol (53).  A high correlation was shown between dietary intake and 
adipose tissue concentration for γ-tocopherol, yet this correlation did not hold for α-
tocopherol (54).  Supplementation of the tocopherols appears to have some effect on 
plasma levels of the other vitamers.  It has been shown that supplementation of α-
tocopherol depresses plasma and tissue γ- levels (55).  In another study, that effect was 
seen, but supplementation with γ-tocopherol had no effect on α-tocopherol 
concentrations (56).  On the other hand, Cement and Bourre fed vitamin E deficient 
rats a diet of a constant α-tocopherol concentration, but graded levels of γ-tocopherol 
(57).  The rats fed the γ-diets showed much higher tissue concentrations of α-
tocopherol than the rats fed α-tocopherol alone and the higher the γ:α ratio, the higher 
the tissue α concentration.  In other studies, γ-tocopherol-deficient weanling rats 
deprived of vitamin E for 13-15 weeks showed tissue α- levels 10% lower than those 
of γ-tocopherol sufficient rats (58).  These studies suggest the ability of α-tocopherol 
to increase the elimination of γ-tocopherol and the ability of γ- to increase the  
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Table 1.2 
Plasma concentrations of vitamin E vitamers (Lee et al, 2003; Chow, 1975). 
 
 
 
 
 
 
 
 
Vitamer (µmol/L)  Average  +/- Standard dev. 
α-TOH 27.3  4.7 
γ-TOH 1.3 0.5 
β-TOH <0.7  - 
δ-TOH 0.1  0.0 
α-T3 0.1 0.1 
γ-T3 0.1  0.1 
δ-T3 0.0  0.0  
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retention of α-tocopherol.  One other possibility that Emmel and Celle suggested is the 
conversion of γ-tocopherol to α-tocopherol by the intestinal microflora, although this 
does not explain the effect of α-TOH on γ-TOH plasma and tissue levels (58).   
Elmadfa et al supported this argument by a generational study done in Wistar rats, in 
which the first 3 generations were supplemented with synthetic γ-tocopherol (59).  In 
the fourth generation, one group was fed a vitamin E free diet and subcutaneously 
injected with γ-tocopherol so as to avoid intestinal dietary tocopherol.  The other 
groups were fed γ-tocopherol as with the first three generations along with additional 
methionine or choline as methyl donors.  The ratio of α-/γ- was calculated as 
transformation rate and it was found that those supplemented with additional methyl 
donors displayed a higher ratio of α-/γ-.  The rats injected with γ-TOH showed a much 
lower ratio of α-/γ-, which the authors said indicated a conversion of γ- to α-TOH by 
the intestinal flora which could then be absorbed through the gut.  Still, no data 
currently exists demonstrating the actual conversion of one dietary form of tocopherol 
to another.  In all cases the body appears to selectively enrich plasma and tissues with 
α-tocopherol while eliminating the non-α forms.   
The fact that the plasma and tissue levels of the tocopherols and tocotrienols do 
not reflect the dietary ratios of these vitamers is a central vitamin E paradox that has 
driven much of the research in vitamin absorption, distribution and elimination until 
now.   
Vitamin E Absorption and Distribution 
  Dietary vitamin E is absorbed mainly in the small intestine in a manner similar 
to other lipid food components.  Esterified (synthetic) forms of the vitamin are 
hydrolyzed prior to absorption.  The free tocopherol is packaged into micelles with 
bile acids and dietary lipids where it is then absorbed with other lipids by means of 
passive diffusion (60).  Studies with thoracic-duct cannulated rats suggested an  
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absorption efficiency of 65% for α- and γ-tocopherol (61).  Fecal recovery of a 
radioactive dose of α-tocopherol in humans has indicated about 70% absorption (62).  
Other studies suggest the tocopherols do not compete for absorption (61).  Cystic 
fibrosis patients displaying impaired lipid absorption likewise display impaired 
tocopherol absorption (63).  Once incorporated into the enterocytes, the vitamers are 
packaged into chylomicrons for secretion into the lymph (64).  The importance of this 
step in regulation of vitamin E status is highlighted by the fact that patients with 
familial abetalipoproteinemia display impaired vitamin E absorption and low plasma 
tocopherol levels (65).  Secretion of tocopherols into chylomicrons peaks in humans 
between 6 and 12 hours after vitamin E administration (66), however the half life of 
tocopherols in these chylomicrons is only 10 to 15 minutes (67).  The newly secreted 
chylomicrons move from the lymph to the thoracic ducts where they enter the blood 
circulation.  Once in the circulation, the core triglycerides of the chylomicrons are 
hydrolyzed by lipoprotein lipase, resulting in the smaller chylomicron remnant 
particles.  During this time the vitamers may be taken up along with free fatty acids 
into peripheral cells as the chylomicrons are hydrolyzed (68), or also transferred to 
HDL.  HDL is able to then transfer its vitamin E contents to other lipoproteins (69,70).  
From here, the vitamin E remaining in the chylomicron remnants are taken into the 
liver.  Investigation of the chylomicron-rich fraction of vitamin E supplemented 
individuals reveals there is no discrimination between the tocopherols prior to uptake 
by the liver (71).  Additionally, the exchange of vitamin E between the lipoproteins is 
non-discriminatory, and therefore equimolar doses of tocopherols result in equimolar 
concentrations in the lipoproteins during the first 6-9 hours after dosing (66).     
  Vitamin E was originally shown to be secreted from the liver with other lipids 
packaged into nascent triglyceride-rich VLDL (72).  The VLDL particles are 
hydrolyzed in the circulation to LDL and the tocopherol is again distributed between  
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all the circulating lipoproteins (73).  However, Arita et al have demonstrated in 
cultured hepatocytes that an inhibitor of Golgi function, Brefeldin A, inhibits VLDL 
secretion but does not affect secretion of α-tocopherol (74).  It is possible that the 
VLDL secretory pathway is functional but not necessary for hepatic secretion of 
vitamin E.  Another mechanism must exist for export of the vitamin from the liver.  
Oram et al have recently demonstrated the ability of the ABC-A1 transporter to 
facilitate the transfer of α-tocopherol from human fibroblasts and murine macrophages 
to plasma Apo-A1 (75).  As the ABC-A1 transporter is expressed on the hepatocyte 
cell membrane, it is postulated that ABC-A1 transport is the mechanism for tocopherol 
secretion from the liver.  This is supported by evidence from mice which lack a 
functional ABC-A1 transporter and are models for Tangiers disease.  This defect 
results in a general deficiency of fat soluble vitamins including vitamin E (76).   
Additionally, fibroblasts from Tangiers patients lack the ability to deliver α -
tocopherol to Apo-A1 (75).   A phospholipid transfer protein in the plasma appears to 
facilitate the transfer of vitamin E between the lipoproteins and cells (77,78).  The 
LDL receptor appears to play a role in vitamin E uptake into cells as radiolabeled α-
tocopherol is incorporated into LDL receptor expressing cells at a higher rate than 
cells lacking the receptor (79).  However, rabbits with a defect in LDL receptor 
expression showed no particular defect in delivery of α-tocopherol to tissues (80), 
suggesting this mechanism of tocopherol delivery is present, but not essential.  α-
Tocopherol is also taken up into hepatocytes by means of selective uptake from HDL, 
possibly by means of the SR-B1 scavenger receptor (81).  The importance of this 
mechanism of cellular tocopherol uptake is indicated by the demonstration that α-
tocopherol uptake from HDL is 5 times higher than from LDL in porcine primary 
endothelial cells (82).  
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While there appears to be no discrimination between the vitamers from 
absorption through hepatic clearance of chylomicron remnants, the hepatic secretion 
of the vitamers into the plasma is highly discriminatory.  Monkeys fed equimolar 
amounts of d6-RRR-α-tocopherol, d3-rac-α-tocopherol, and d2-RRR-γ-tocopherol 
showed a VLDL fraction containing 80% d6-RRR-α-tocopherol after 24 hours, 
demonstrating post hepatic discrimination of non-α vitamers as well as synthetic 
forms (83).  The subsequent distribution of the vitamers between lipoproteins and into 
tissues therefore reflects this discrimination.  Figure 1.3 depicts this pathway of 
tocopherol uptake and distribution.  It is now clear that the liver is the main site of 
Vitamin E vitamer discrimination. 
The post-absorptive selectivity for α-tocopherol compared with the other 
vitamers has been attempted to be explained by various mechanisms.  It has been 
suggested that biliary excretion of the tocopherols favors the non α- forms resulting in 
preferential α-tocopherol retention.  Non-supplemented patients with an indwelling t-
tube in the bile ducts displayed no appreciable differences in the α/γ ratio in the bile 
when compared with plasma samples (84).  In a patient supplemented with large 
equivalent doses of all-rac-α- and RRR-γ-tocopherol, biliary α-TOH excretion 
decreased while the γ-TOH excretion increased over the first 8 hours.  After that, the 
tocopherols were found in the bile in ratios similar to that of the plasma, leading the 
authors to conclude that while γ- is secreted indiscriminately into the bile, α-
tocopherol is preferentially secreted from the liver into lipoproteins until the 
mechanism for recognition is saturated, after which both tocopherols are 
nonspecifically secreted into the bile (84).  The biliary route of tocopherol elimination 
was explored as a means of vitamer discrimination by Yamashita et al in which rats 
were fed diets containing either 300 mg/kg α-tocopherol, γ-tocopherol, a mix of the 
two, or γ-tocopherol + sesame seed (85).  The plasma, liver, and bile concentrations of  
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Figure 1.3 
Vitamin E absorption and distribution.  Relative amounts of α-TOH (α) or other 
vitamers (γ) distributed in the diet and body are depicted by character size. 
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tocopherol were measured.  The plasma, liver, and bile ratios of α- and γ- were very 
closely correlated in all groups.  This included the γ + sesame group which showed a 
marked increase in γ-tocopherol concentrations in liver, plasma and bile.  Under the 
conditions of biliary excretion being the main route of non-α-tocopherol elimination, 
one would expect an increase in plasma/tissue γ-tocopherol concentrations to be 
marked by a correlating decrease in biliary excretion.  The opposite effect was seen, 
suggesting biliary tocopherol excretion is rather a marker for tocopherol liver 
concentrations.  
Sesame Oil and Vitamin E Plasma and Tissue Concentrations 
The effect of sesame dietary sesame components on plasma and tissue 
tocopherol components has been explored in several other studies, especially the effect 
of the lignan components of sesame oil, sesamin and sesaminol (Figure 1.4).  
Yamashita et al first noted this effect while studying the effects of a mix of tocopherol 
and sesame lignans on indices of oxidative stress in rats (86).  Rats were fed 4 diets: 
vitamin E-free control, α-tocopherol, γ-tocopherol, γ + sesaminol, and γ + sesamin.  
All tocopherols were at 50 mg/kg diet.  Neither sesaminol nor sesamin affected plasma 
or liver concentrations of α-tocopherol to a significant level when compared with 
control.  γ-Tocopherol on the other hand was elevated between 2-4 times the 
concentration of α-tocopherol in both plasma and liver.  This was still only half the 
concentration of α-tocopherol in the α-supplemented group, but these levels of γ-
tocopherol were able to increase the bioactivity of γ-tocopherol to levels matching 
those of α-tocopherol in plasma and liver lipid peroxide, RBC hemolysis, and 
pyruvate kinase measures of oxidative stress.  This in turn suggests that it is the 
greater plasma and tissue concentrations that dictate the superiority of α-tocopherol in 
bioactivity measurements over the other vitamers, rather than intrinsic differences in 
chemical reactivity.  Diets containing both α- and γ-tocopherol with sesame lignans  
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Figure 1.4 
The effects of sesame lignans on plasma and liver concentrations of α- and γ-TOH in 
rats fed experimental diets for 8 weeks.  Data is shown as means +/- standard error, n 
= 6.  n.d. = not detected.  (Yamashita et al, 1992). 
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were also shown to raise γ-tocopherol plasma levels with minimal effect on α levels in 
rats (87).  Similar effects are seen in humans fed diets containing sesame seed (88).  It 
appears that components of sesame are able to affect the mechanism(s) that regulate 
elimination of the non-α vitamers, although the mechanism was not identified in these 
studies. 
Tocopherol Transfer Protein 
In 1975 a cytosolic protein was identified in rat liver which bound α-
tocopherol.  This protein was later found to transfer tocopherol between membranes 
and it is therefore designated α-Tocopherol Transfer Protein or α-TTP (89).  This 
protein along with the so called tocopherol binding protein (TBP) and tocopherol 
associated protein (TAP) are members of the Sec 14 family of lipid binding and 
transfer proteins (90).  While the liver appears to be the main site of expression of α-
TTP, messenger RNA has been detected in brain, spleen, lung, kidney, and placenta 
(91-93).   
The membrane transfer function of α-TTP was used to test its activity toward 
various forms of vitamin E (94).  The ability of the vitamers to compete with α-
tocopherol for transfer between mitochondrial membranes and liposomes 
demonstrated the specificity of α-TTP for transferring α-tocopherol (Table 1.3).  α-
TTP stimulated α-tocopherol secretion from α-TTP-expressing McARH7777 hepatic 
cells (74).  The function of α-TTP in hepatocytes is therefore presumed to be in 
selectively regulating the transport of α-tocopherol between membranes, resulting in 
the enhanced secretion of α-TOH into the plasma.  The lower binding affinity of the 
other vitamers would then result in less secretion of these non-α- forms into the 
plasma.  The same study by Arita et al indicated that this TTP-facilitated secretion did 
not occur via enhanced packaging of α-tocopherol into nascent VLDL as previously  
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Table 1.3 
Relative affinities of vitamin E vitamers for the α-tocopherol transfer protein.  The 
rate of transfer of radiolabeled RRR-α-TOH between membranes was calculated.  A 
50 fold excess of each vitamer was tested for competition with the radiolabeled RRR-
α-TOH for transfer.  Relative affinities for each vitamer are expressed as a percentage 
of RRR-α-TOH value.  Data are expressed as mean +/- standard error. (Hosomi et al, 
1998) 
 
 
 
 
 
 
 
 
Vitamer  Relative Affinity (%)  Standard error 
RRR-α-TOH 100  - 
SRR-α-TOH 10.5  0.4 
γ-TOH 8.9  0.6 
β-TOH 38.1  9.3 
δ-TOH 1.6  0.3 
α-T3 12.4  2.3  
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assumed, as TTP-facilitated secretion occurred when VLDL synthesis was chemically 
blocked.   
The importance of α-TTP in vitamin E status is highlighted by a vitamin E 
deficiency syndrome termed AVED (ataxia with vitamin E deficiency).  Mutations in 
the α-TTP gene were found to result in this syndrome, and patients had to be highly 
supplemented with α-tocopherol to overcome the nervous system disorder symptoms 
(95,96).  α-TTP knockout mice display the symptoms of AVED patients and 
extremely low plasma and tissue tocopherol levels (97,98).  As α-TTP does show 
some binding affinity for non-α-tocopherols, it may also aid in the secretion (albeit 
low secretion) of non-α forms of the vitamin, as evidenced by the fact that in α-TTP 
compromised mice, plasma γ-tocopherol levels also decrease although not to the same 
extent as α-tocopherol (98).  Additionally, tissue ratios of RRR-α- to rac-α-tocopherol 
levels were around 2 in control mice, but only 1 in TTP knockouts, suggesting TTP 
preferentially secretes the 2R diastereomers over the 2S diastereomers (97).  There is 
some evidence of up-regulation of α-TTP by vitamin E deficiency although the 
literature is equivocal on this subject (29,30).  In all cases, the data clearly indicates 
this protein is an important regulator of plasma and tissue tocopherol status with a 
selective preference toward α-tocopherol.  However, α-TTP alone is not sufficient to 
explain the lower levels of non-α-tocopherols found in plasma and virtually all tissues 
despite their predominance in the diet.  Based on the current theory of α-TTP-
mediated transfer of α-tocopherol out of the liver, the body must possess another 
mechanism for eliminating the remaining tocopherols, as there is no evidence of a 
build-up of non-α vitamers in the liver or other tissues.  Additionally, there is no 
increase of α-tocopherol excretion in the bile of α-TTP knockout mice (97).  Another 
route must therefore exist to explain tocopherol elimination.  
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Vitamin E Catabolism and Excretion 
Simon and colleagues described the presence of an apparent metabolite of α-
tocopherol in human urine (99,100).  These metabolites, tocopheronic acid and its 
tocopheronolactone, commonly referred to as the Simon metabolites, were the side-
chain shortened carboxyl derivatives of α-tocopherol, whose chromanol head group 
had been oxidized to the corresponding quinone (Figure 1.5).  Nearly half a century 
later, Schonfeld et al identified another metabolite of α-tocopherol, the 2,5,7,8-2(2’-
carboxyethyl)-6-hydroxychroman  α-CEHC (Figure 1.5) (101).  This metabolite 
differed from the Simon metabolites in that it possessed an intact (non-oxidized) 
chromanol head group.  All of the metabolites were present in urine as glucuronide 
conjugates.  It is in question whether the Simon metabolites are truly metabolic results 
of enzymatic activity, or simply artifacts of the extraction and analytical procedures 
used by Simon’s group (102).  The analogous γ-CEHC and δ-CEHC metabolites have 
also been identified, each being found in the conjugated form in urine (Figure 1.5) 
(36,103).  The tocotrienols also are metabolized to the corresponding CEHC 
metabolite (104,105).  As the side chain is truncated to the 3’ carbon of the 
tocotrienols, all double bonds are removed and the CEHC metabolites of the 
tocotrienols are therefore identical to the CEHC metabolites of the corresponding 
tocopherol (Figure 1.5).  Interestingly, the γ-CEHC metabolite was originally 
identified as a natriuretic factor, while this activity was not noted for the α- form (36). 
While the CEHC metabolites were discovered in the urine, their presence has 
also been detected in both the plasma and bile (106,107).  Supplementation of the diet 
with  α- or γ-TOH increases the concentration of their CEHC metabolites in the 
plasma, raising the question as to whether the plasma concentration of the α-CEHC 
may be used as a measure of an adequate vitamin E supply (102,106).  Patients with 
end-stage renal disease show accumulation of CEHC metabolites in the plasma, which  
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Figure 1.5 
Vitamin E Vitamers and their metabolites identified in urine 
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may suggest that renal filtration plays a role in determining plasma CEHC 
concentrations (108,109).   
Given the natriuretic activity of γ-CEHC, there has been considerable interest 
in the role of tocopherols as precursors to active metabolites.  The intact chromanol 
ring of the CEHC metabolites suggested they might possess antioxidant activity as is 
the case for their tocopherol and tocotrienol precursors.  Indeed the CEHC metabolites 
posses the ability to scavenge radicals, but this activity seems to be mainly relegated to 
the aqueous environment, whereas tocopherol antioxidant activity lies mainly in the 
hydrophobic environment of membranes (20).  γ-CEHC is able to inhibit 
cyclooxygenase-2-mediated synthesis of PGE2, resulting in an anti-inflammatory 
activity greater than γ-TOH, α-TOH or α-CEHC (110).   
Metabolism as a Potential Mechanism of Regulation of Vitamin E Status 
The identification of urinary metabolites of vitamin E suggested a potential 
role of metabolism in regulating plasma and tissue vitamin E status.  As described, the 
tissue and circulating ratio of α-/γ-tocopherol strongly favors α-tocopherol, under 
virtually all normal dietary conditions.  Quantification of plasma α- and γ-CEHC 
metabolites revealed a 10-fold difference in baseline levels, favoring γ-CEHC (106).  
Similarly, while studies using deuterium-labeled RRR- and rac-α-tocopherol reveal a 
preferential retention of the natural RRR form, the synthetic form is preferentially 
excreted as α-CEHC in human urine (111).  Swanson et al used deuterium labeled γ-
CEHC to accurately determine the concentration of γ-CEHC in human urine (112).  
Based on estimates of typical daily γ-tocopherol intake, the authors concluded that 
urinary excretion of the CEHC metabolite is the major route of elimination of γ-
tocopherol in humans.  This identified a route for elimination of the vitamers not 
retained after post-absorptive uptake into the liver.  Further evidence of the importance 
of this route in regulation of tocopherol (vitamin E) status is given by the comparison  
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of α-CEHC excretion by patients with defects in α-TTP and control patients (113).  
The α-TTP defective patients showed excretion of α-CEHC significantly above that of 
controls, suggesting α-TTP is protecting α-tocopherol from enzymatic elimination.  
The enzymatic elimination of tocopherols may additionally explain the effects of α-
tocopherol supplementation on plasma and tissue γ-tocopherol levels.  It has recently 
been demonstrated that vitamin E-deficient rats fed 10 mg each α- and γ-tocopherol 
showed a greater increase in γ-CEHC urinary excretion than rats fed 10 mg γ-
tocopherol alone (114). 
The mechanism behind the metabolism of vitamin E to their CEHC 
metabolites was speculated to be based on an ω-oxidation of the phytyl tail, followed 
by sequential removal of 2-3 carbons by a mechanism similar to the β-oxidation of 
fatty acids (103).  This speculation was based solely on comparison of the molecular 
structures of δ-tocopherol with its CEHC metabolite.  Additional evidence in support 
of such a mechanism came with the identification by Parker and Swanson of a 5’-
carboxychromanol analog of the γ-CEHC metabolite in HepG2 hepatoblastoma cell 
culture incubated with γ-tocopherol and in human urine (115).  This molecule differed 
from CEHC by the addition of 3 carbon units on the phytyl tail, making it the potential 
β-oxidation precursor of the γ-CEHC molecule.  Additionally, this was the first report 
of a cell culture model that would carry out catabolism of tocopherols to their urinary 
metabolites.  The analogous α-5’-carboxychromanol was identified in the urine of 
patients with a defect in α-TTP (113).  The development of a cell culture model of 
vitamin E catabolism provided a powerful tool for characterizing this catabolic 
pathway.  The putative ω-oxidation step in the metabolism of tocopherols, as proposed 
by Chiku et al, suggested the involvement of a cytochrome P450 enzyme, as several 
such enzymes are known to catalyze the hydroxylation of hydrophobic molecules  
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The Cytochrome P450 Family 
Cytochrome P450 (CYP) enzymes (isozymes) are the name for a superfamily 
of thiolate hemeproteins that, when complexed with carbon monoxide, give a 
maximum absorbance at 450 nm.  The many P450 isozymes are divided into different 
subfamilies based on sequence homology of the genes that encode them.  Since their 
discovery over half a century ago, more than five hundred P450 enzymes have been 
identified, cloned and sequenced (116) and are divided into families by having > 40% 
gene sequence homology (e.g. CYP1) and into subfamilies based on > 55% sequence 
homology (e.g.CYP1A).  Each enzyme within the subfamily is numbered as specific 
isoforms according to the order in which they were discovered (e.g. CYP1A1). 
The P450s display a wide variety of catalytic functions.  The main function 
appears to be in the transfer of one oxygen atom of O2 to a substrate as in 
monooxygenation reactions:   
  RH + O2 + 2e
- + 2H Æ ROH + H2O 
These enzymes may also catalyze C-C or C=N bond cleavage, reductions, 
dehydrations dehydrogenations, or isomerizations (117).  There are two main roles 
that these functions play.  The first is in catalyzing the reactions needed for the 
biosynthesis or degradation of endogenous compounds such as steroids.  The other 
role is in the biotransformation of exogenous compounds to forms that are useful to 
the organism, forms that are readily excreted from the organism, or in a negative 
fashion, forms that can be potentially harmful to the organism.  This first catabolic 
process is known as phase 1 metabolism.  Phase II metabolism often accompanies this 
in which the newly modified compound is conjugated with a glucuronide, sulfate or 
other such moiety, usually rendering the molecule substantially more water soluble, 
and readily able to be excreted in the urine or bile.  Many individual P450 enzymes are 
able to metabolize several substrates, often of remarkably different chemical structure.   
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The CYP1, 2, and 3 families appear to be mainly responsible for the metabolism of 
xenobiotics, while the others are more specific to transformation of endogenous 
substances (118). 
  On a tissue basis, there are varying P450 isozymes expressed in all tissues, 
however the liver is the main site of expression (119). The expression of enzymes 
within a subfamily may differ from tissue to tissue as is the case for such P450’s as 
CYP1A1 and 1A2 which are found at their highest levels in the lung and liver, 
respectively (120).  The expression of P450 isoforms may also change depending on 
age, with the CYP3A7 isoform abundantly expressed in fetal liver, yet after birth, 
levels of this isoform decrease while expression of the CYP3A4 (adult) isoform 
increases (121).  The expression levels of individual P450 enzymes varies greatly, 
with the CYP3A4 isoform being the most highly expressed, making up nearly 30% of 
the P450 found in the liver (Table 1.4) (122).  Other P450s are expressed at lower 
levels, some representing less than 1% of the total hepatic P450.  Caution must be 
taken in the estimates of hepatic P450 content when the concentrations of individual 
P450 enzymes are measured using immunoblot analysis and the total P450 content is 
measured using CO-reduced difference spectra, as this may lead to over-estimations of 
the percentage of individual P450 content (123). 
The abundance of the P450 enzymes in the liver makes this tissue the main site 
of drug metabolism and results in what is called the “first pass effect”.  Orally 
administered drugs or components of food that are absorbed through the gut may be 
partially metabolized by intestinal P450 enzymes, but quickly make their way to the 
liver before distribution throughout the body.  Before leaving the liver, some fraction 
of the dose is metabolized by hepatic P450s, often leading to a greatly diminished 
plasma concentration of the active compound.  This means the effective administered 
dose of a drug may be much greater than the actual amount needed post-hepatically.   
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Table 1.4 
Major Human Cytochrome P450 enzymes in the liver as a percentage of total hepatic 
P450 and the extent to which the levels may vary by subject (Rendic and DiCarlo, 
1997; Powell et al, 1998 (CYP4A); Jin et al, 1998 (CYP4F)).   
* Specific P450 measured by immunoblot, total P450 measured by CO-reduced 
difference spectrum.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CYP Enzyme  Level of Enzyme 
(% of total) 
Extent of Variability  
in Level 
1A2 13  40  fold 
1B1 <  1   
2A6 4 30-100  fold 
2B6  < 1  50 fold 
2C 18  25-100  fold 
2D6  Up to 2.5  >1000 fold 
2E1  Up to 7  20 fold 
2F1  No data  No data 
2J2  No data  No data 
3A4  Up to 28  20 fold 
4ª  Up to 20 *  No data 
4F  Up to 40 *  No data  
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While the P450 enzymes are protective against harmful xenobiotics, they also 
decrease the effectivity of desired compounds.  On the downside, the metabolism of 
drugs by these enzymes often results in metabolites which are more toxic than their 
parent compound.  As a result, drug dosage and P450 induction and inhibition must be 
carefully monitored so as to avoid drug toxicity.   
P450 Induction 
On an individual enzyme basis many of the P450s are very sensitive to 
induction or down-regulation by inducers or inhibitors (124).  Endogenous 
compounds, as well as those from the environment or diet, can increase gene 
expression of individual cytochrome P450s by affecting nuclear receptor binding 
regions or other factors in the promoter region of the P450 gene.  These mechanisms 
of induction have been thoroughly characterized for P450s such as the highly 
inducible CYP1A1 (124).  The induction of a P450 enzyme can therefore have 
dramatic effects on the clearance of a substrate, as is the case for the anticoagulant 
warfarin, whose treatment dose must be increased up to 10 fold during simultaneous 
treatment with the P450 inducer phenobarbital (125).   
P450 Inhibition 
Inhibitors of cytochrome P450s have proven a powerful tool in the 
identification of the individual P450 isozymes that are involved in specific reactions.  
Potent inhibitors of certain P450 enzymes often have no effect on others.  However, in 
many cases, the specificity of an inhibitor for the P450 is highly dependent on the 
inhibitor being used.  The antifungal ketoconazole has been commonly reported as a 
very specific inhibitor of CYP3A4 at low concentrations (<10 µM) but a non-specific 
P450 inhibitor at high (>100 µM) concentrations (126).  The role of CYP3A in the 
metabolism of many substrates has been assumed based on the inhibition of substrate 
metabolism by low concentrations of ketoconazole.  In the case of ketoconazole, it is  
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able to act as a competitive inhibitor of CYP3A, as evidenced by kinetic inhibition 
analysis (127).  Other forms of inhibition of P450s include non-competitive inhibition, 
in which increasing substrate concentration does not alter inhibition, and also 
mechanism based inhibition, in which a metabolite of the P450 substrate is what 
inhibits the enzyme.  Suicide inhibition occurs when the inhibitor is permanently 
complexed with the enzyme and the protein is unalterably non-functional.  
P450 Polymorphisms 
Activity of the P450s can additionally vary greatly on an interindividual basis.  
While some of this is driven by P450 induction or inhibition by environmental factors 
such as diet, much of individual variation in P450 expression and activity can result 
from the polymorphisms known to occur within a P450 gene sequence.  One of the 
best described examples of this is in the polymorphic CYP2D6 gene.  This 
polymorphism occurs in about 7% of Caucasians and leads to an absence of a 
functional CYP2D6 protein (128,129).  Individuals with this variation are known as 
“poor metabolizers” versus those who have the active protein, “extensive 
metabolizers” and are identified by their ability to metabolize key compounds such as 
bufuralol or dextromethorphan (130,131).  The opposing polymorphism has also been 
identified in which individuals carry multiple copies of the CYP2D6 gene and 
therefore display even greater substrate metabolism than the general population (132).    
P450s are Organized in a Membrane-Associated Electron Transfer Complex 
On a cellular level, human cytochrome P450s are found in membranes, mainly 
in the endoplasmic reticulum of cells, although they also may exist in mitochondria 
and other organelles (133).  As membrane bound proteins, the crystal structures of the 
various isoforms have not been easily elucidated.  X-ray crystallography, along with 
other methods, has provided evidence of a conformation for the enzyme which places 
the substrate access channel facing the membrane (134,135).  This is logical, as many  
 
 
31 
of the substrates of this enzyme family are hydrophobic molecules which would favor 
their incorporation into the membrane.  Studies using liposome-bound (reconstituted) 
cytochrome P450 has supported the idea that at least some P450 enzymes may bind 
their substrates directly from the membrane (136).   
Within the membrane, the cytochrome P450 exists as part of a multi-protein 
complex.  In order to carry out the oxidative reactions they are best known for, the 
enzymes must have a source of electrons.  The cofactors NADPH or NADH provide 
the electrons for the reaction, making P450 activity completely dependent on the 
presence of these cofactors.  The electrons are transferred to the enzyme through the 
action of the FAD- and FMN-containing cytochrome P450 reductase in the ER 
(Figure 1.6).  Mitochondrial P450s receive their electrons in a two-step process, first 
from ferredoxin reductase to ferredoxin, which then transfers the electrons to the P450 
enzyme.  Often, cytochrome b5 is associated with the P450-reductase complex, acting 
as a positive modifier of the P450 monooxygenase reaction (137).   
Cooperativity in P450 Kinetic Activity 
The kinetics of most P450 enzymes toward their substrates can be described 
with simple hyperbolic Michaelis-Menten kinetics.  However, recent work in P450 
biochemistry has identified an allosteric effect for certain enzyme-substrate 
interactions.  The CYP3A4, 1A2, and 2C9 isoforms have been characterized as 
displaying positive or negative cooperativity when challenged with certain substrates, 
resulting in sigmoidal or biphasic kinetics, respectively (138-140).  These allosteric 
effects can take place by two different binding scenarios.  In the first, the binding sites 
on the enzyme are in two distinct sites.  The cooperative effect occurs when either one 
molecule of the substrate (homotropic) or a molecule different than the substrate 
(heterotropic) binds one site, changing the affinity of the enzyme for its substrate 
and/or increase the rate of product formation.  In the second, the binding pocket of the  
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Figure 1.6  
Electron Transfer from NADPH to Substrate by the cytochrome P450 multi-protein 
complex (Two-electron acceptor complex model, Shenkman and Jansson, 2003). 
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enzyme is large enough for entry of the substrate and the effector molecule which then 
results in the cooperativity.  Kinetic studies as well as molecular modeling seem to 
support the binding of two molecules within one binding site (139,141,142).  
Identification of a Potential Tocopherol-ω-hydroxylase P450 
  The identification of the 3’- and 5’ carboxychromanol metabolites in the media 
of HepG2 hepatoblastoma cells incubated with γ-tocopherol provided a model for 
identifying the P450 enzyme(s) involved in the catabolism of the tocopherols (115).  
Taking advantage of the use of the reported specificity of inhibitors of individual P450 
isoforms, our lab reported >90% inhibition of γ- and α-tocopherol metabolism to their 
3’- and 5’-carboxychromanols by 1µM ketoconazole (143).  This effect was not seen 
with inhibitors of several other P450s.  This result strongly implicated CYP3A4 as the 
human P450 responsible for the ω-hydroxylation of the tocopherols, as ketoconazole 
is reportedly specific for CYP3A4 at 1 µM (144).   The identification of P450-based 
inhibition of tocopherol metabolism suggested the possibility of alterations in plasma 
and tissue tocopherol status being regulated by inhibition of the P450 involved.  The 
aforementioned influence of sesame lignans such as sesamin on tocopherol status was 
suspected to be an example of this inhibition.   Sesamin was originally reported to be 
an insecticide synergist (145).  These synergists often function by inhibiting insect 
P450 enzymes which detoxify insecticides.  This increases the insecticide half-life, 
rendering it more potent at lower concentrations (146,147).  We demonstrated that 
1µM sesamin is as effective as ketoconazole at inhibiting tocopherol metabolism in 
HepG2 cultures, indicating that inhibition of tocopherol catabolism is indeed the 
mechanism by which sesame oil or its lignans modify plasma and tissue tocopherol 
status in vivo (143).  This reported effect led to a follow-up study by Ikeda et al which 
demonstrated that dietary sesame seed, sesame lignans, and ketoconazole inhibit the 
excretion of γ-CEHC into urine of rats fed γ-tocopherol.  This represented an in vivo  
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conformation of our studies, clearly demonstrating the physiological importance of 
this catabolic pathway to vitamin E status in vivo. 
  The inhibition of tocopherol metabolism by ketoconazole suggested the role of 
CYP3A4 in the catabolic pathway, based on the reported specificity of ketoconazole 
for this isozyme.  Birringer et al reported a 5-fold induction of rac-α-tocopherol 
metabolism by pre-treatment with rifampicin and suggested it confirmed the 
involvement of the CYP3A4 enzyme (148).  Rifampicin has been characterized as an 
inducer of CYP3A.  It is however by no means specific to this isoform, being also an 
inducer of numerous other P450 enzymes, especially of the CYP2C family (124).  The 
possibility that other cytochrome P450 enzymes could be involved in the metabolism 
of the tocopherols could not be discounted.   
Cytochrome P450 4F2 
The presence of the phytyl tail as a major structural feature of vitamin E led us 
to explore the involvement of P450 enzymes known to ω-hydroxylate lipids 
possessing a carbon tail analogous to vitamin E.  While the CYP1, CYP2 and CYP3 
family of P450 enzymes play a large role in the metabolism of xenobiotics, the CYP4 
family is mainly involved in the ω-hydroxylation of fatty acids and eicosanoids, both 
possessing long chain carbon tails as is the case for vitamin E.  The hepatic CYP4F 
enzyme, CYP4F2 was identified by Kikuta et al as an LTB4 ω-hydroxylase enzyme in 
the liver (149).  This was not the first example of LTB4 ω-hydroxylation by a member 
of the CYP4F family.  It was earlier known that LTB4 ω-hydroxylation was catalyzed 
by a P450 in human neutrophils (150).  Kikuta’s group then identified cDNA from 
neutrophils that gave rise to a protein possessing LTB4-ω-hydroxylase activity.   
Analysis of the DNA sequence demonstrated this gene to be part of a new P450 
subfamily, the CYP4F family and was designated CYP4F3 (151).   Analysis of the 
cDNA of CYP4F2 revealed it possessed over 87% sequence homology with CYP4F3,  
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although CYP4F2 is not expressed in neutrophils, nor is neutrophil CYP4F3 expressed 
in the liver (149).  The main differences in the two proteins are at positions 66-114 
which only share 27% homology, whereas the rest of the proteins sequence is 93% 
homologous.  This low homology region corresponds to the open end of the substrate 
binding pocket when compared with the primary sequence of CYP102, whose 3D 
structure was previously determined (152).  This region is found in exon 3 of the 
CYP4F2 gene and exon 4 of the neutrophil CYP4F3 gene (153).  It now is evident that 
neutrophil CYP4F3 is an alternative splice variant, as a hepatic isoform from the same 
gene has been described which undergoes the same splicing as CYP4F2 in which exon 
3 is included and exon 4 removed and was designated CYP4F3B (153).  The 
importance of this region in substrate specificity is indicated by the low Km of 
CYP4F3A for LTB4, in contrast to both 4F2 and 4F3B which have high Km values for 
LTB4 (153).  Additionally, the Km of 4F3A for conversion of arachidonic acid to it’s 
vasoactive metabolite 20-HETE is high, while it is low for both CYP4F2 and 4F3B 
((154,155).  This is likely explained again by the high degree of sequence homology 
(80%) of exon 3 between CYP4F2 and 4F3B (154).  Unlike the neutrophil CYP4F3A, 
both CYP4F2 and CYP4F3B have a wide tissue distribution.  The liver is their 
principle location, but they are also found in kidney, prostate, small intestine, and 
trachea and in each case mRNA levels of CYP4F3B are 2-5-fold higher than that of 
CYP4F2 (154).  
 LTB4 normally functions as a chemotactic and chemokinetic agent.  It is able 
to recruit and activate neutrophils, leading to an inflammatory response.  CYP4F 
enzymes in neutrophils and the liver play a large role in regulating this inflammatory 
response.  Upon recruitment of neutrophils to a site of inflammation, CYP4F3A 
converts LTB4 to the inactive 20-OH-LTB4, leading to less inflammatory activity.    
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Likewise, the liver is the major organ for elimination of LTB4 and thus the presence of 
CYP4F2 and 3B may regulate the overall levels of LTB4 in the body (156,157).   
  The other major metabolite of the CYP4F family is 20-
Hydroxyeicosatetraenoic Acid (20-HETE), derived from 20-hydroxylation of 
arachidonic acid.  This metabolite inhibits Na
+/K
+-ATPase, is a potent vasoconstrictor 
by means of Ca
2+-activated potassium channels, and induces hypertension in rats (158-
161).  The presence of CYP4F2 and 3B in the kidney and lungs appear to play a large 
role in the production of this metabolite (155).  Other functions of CYP4F2 include ω-
oxidation of 6-trans-LTB4, Lipoxin A4, other HETEs, and fatty acid epoxides, as well 
as deethylase and demethylase activities toward ethoxycoumarin and p-nitroanisole, 
respectively (162,163). 
Inhibitors of CYP4Fs have only recently been characterized.  Inhibitors of 
CYP4A ω-hydroxylation of arachidonic acid such as 10-Undecynyl Sulfate and N-
methylsulfonyl-6-(2-propargyloxyphenyl)hexanoic acid showed weak effects on 
CYP4F activity, however, 17-Octadecynoic acid was very potent, with an IC50 of 1-5 
µM (164).  Ketoconazole, which has long been considered a specific inhibitor of 
CYP3A at low concentrations, inhibited 50% of LTB4 20-hydroxylation by CYP4F at 
a concentration of only 10 µM (165). 
As LTB4 is a ligand for the Peroxisome Proliferator Activated Receptor 
(PPAR) orphan nuclear receptor (166), it was suspected that this receptor may be 
involved in CYP4F gene expression.  While the CYP4A family is upregulated by the 
activity of PPAR, there is no evidence for an effect on CYP4F expression (167).  On 
the other hand, the CYP4F gene promoter region contains many nuclear regulatory 
element sequences, including an interferon regulator factor, NF-kβ nuclear factor, 
retinoic acid receptor, retinoid X receptor, and a thyroid hormone receptor sequence 
(168).  The promoter region of CYP4F2 shows a strong response to the presence of  
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retinoic acid and lauric acid, but not peroxisome proliferators, suggesting these 
response elements may play an important role in the regulation of CYP4F2 gene 
expression (167). 
Several cell culture models for CYP4F2 activity have been developed.  The 
hepatoblastoma HepG2 and lung adenocarcinoma A549 cell lines both exhibit 
constitutive expression of CYP4F2, making these cell lines useful tools in the study of 
4F2 activities (169,170).  Additionally, the expression of CYP4F2 in yeast, bacteria, 
and insect cells have shown it to be active for in vitro analysis (149,162) [BD 
Gentest]. 
 
Objectives and Specific Aims 
  The overall objective of the work presented here was to characterize the 
pathway by which vitamin E is metabolized to its water soluble urinary metabolites.  
Specific aims of the study included the following: 
1.  To identify the reactions and intermediates in the pathway involving the ω-
oxidation of tocopherols to their CEHC metabolites. 
2.  To verify the involvement of CYP3A in tocopherol ω-oxidation. 
3.  To determine if other Cytochrome P450 enzymes are involved in tocopherol 
metabolism. 
4.  To develop an in vitro microsomal system for characterizing the enzymology 
of vitamin E metabolism by cytochrome P450 isozymes. 
5.  To verify that sesamin acts specifically at an initial ω-hydroxylation step of 
tocopherol metabolism through the inhibition of a cytochrome P450 enzyme. 
6.  To assess any identified tocopherol-ω-hydroxylation enzymes for their levels 
of activity toward α- and γ-TOH, in order to determine if differences in  
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substrate specificity of the enzyme are able to explain the differences in 
retention of α over γ-tocopherol in vivo. 
7.  To compare the importance of the specific structural features of the various 
isoforms of vitamin E in determining substrate affinity and activity of the 
tocopherol-ω-hydroxylase enzyme.  
8.  To determine if α-tocopherol enhances microsomal metabolism of the other 
tocopherols or tocotrienols, and thus provide a mechanism of how 
supplementation with α-tocopherol depresses plasma levels of other 
tocopherols. 
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Abstract   
Post-absorptive elimination of the various forms of vitamin E appears to play a 
key role in regulation of tissue tocopherol concentrations, but mechanisms of 
tocopherol metabolism have not been elucidated.  Here we describe a pathway 
involving cytochrome P450-mediated ω-hydroxylation of the tocopherol phytyl side 
chain, followed by stepwise removal of two- or three-carbon moieties, ultimately 
yielding the 3’-carboxychromanol metabolite that is excreted in urine.  All key 
intermediates of γ-tocopherol metabolism via this pathway were identified in 
hepatocyte cultures using gas chromatography-mass spectrometry.  NADPH-
dependent synthesis of the initial γ- and α-tocopherol 13’-hydroxy- and carboxy- 
metabolites was demonstrated in rat and human liver microsomes.  Functional analysis 
of several recombinant human liver P450 enzymes revealed that tocopherol-ω-
hydroxylase activity was associated only with CYP4F2, which also catalyzes ω-
hydroxylation of leukotriene B4 and arachidonic acid.  Tocopherol-ω-hydroxylase 
exhibited similar binding affinities but markedly higher catalytic activities for γ-
tocopherol than α-tocopherol, suggesting a role for this pathway in the preferential 
physiological retention of α-tocopherol and elimination of γ-tocopherol.  Sesamin 
potently inhibited tocopherol-ω-hydroxylase activity exhibited by CYP4F2 and rat or 
human liver microsomes.  Since dietary sesamin also results in elevated tocopherol 
levels in vivo, this pathway appears to represent a functionally significant means of 
regulating vitamin E status.  
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Introduction 
The tocopherol and tocotrienol vitamers that comprise the vitamin E family are 
considered the most important lipophilic radical-quenching antioxidants in cell 
membranes.  While their function is most often associated with reduction of peroxyl 
radicals, novel vitamer-specific roles for tocopherols in signal transduction, and in the 
quenching of other reactive chemical species such as nitrogen dioxide and 
peroxynitrite are now being investigated (1).  While much attention has been devoted 
to α-tocopherol (α-TOH) recent studies indicate several of these important roles may 
be specific to γ-tocopherol (γ-TOH) (2).  The mechanisms that regulate tissue 
concentrations and relative proportions of these tocopherols (vitamin E status) are not 
well understood.  Two lines of evidence suggest that vitamin E status is regulated.  
First, large increases in intake of α-TOH result in only small increases in its plasma 
concentration (3).  Secondly, the relative proportions of tocopherols in plasma and 
tissues do not reflect those of the diet.  Tissues selectively incorporate RRR-α-TOH 
even when other tocopherols are consumed in greater proportions.  γ-TOH is the major 
form of vitamin E in the North American diet yet this vitamer occurs in blood and 
tissues at much lower concentrations than that of α-TOH (4, 5). Since tocopherol 
absorption apparently occurs via passive diffusion with similar efficiency among the 
vitamers (6, 7), there clearly exist post-absorptive, vitamer-selective processes that 
ultimately determine vitamin E status.  To date only one protein with vitamer-selective 
properties, α-tocopherol transfer protein (TTP), has been characterized as playing a 
role in vitamin E status.  This protein selectively facilitates hepatic secretion of α-
TOH into the bloodstream relative to other tocopherols, and its absence precipitates 
vitamin E deficiency in humans and mice despite adequate dietary vitamin E (8, 9).  
The metabolic fate of tocopherols that are poorly retained (e.g. γ-TOH) has not been 
characterized.   
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We postulated the existence of an enzyme-mediated mechanism that results in 
the preferential elimination of γ-TOH relative to α-TOH.  Water-soluble metabolites 
of the three major dietary tocopherols, α-, γ-, and δ-TOH in which the phytyl tail is 
truncated to the 3’ carbon without modification of the chromanol head group, have 
been reported to occur in urine (10, 11, 12).  Building on these findings, we reported 
that in non-supplemented individuals a substantial proportion of estimated daily intake 
of γ-TOH is excreted in human urine as its 3’-carboxychromanol metabolite, 2,7,8-
trimethyl-2-(β-carboxyethyl)-6-hydroxychroman (γ-CEHC) (13), but a much smaller 
proportion of α-TOH intake was excreted as α-CEHC, implicating this pathway in the 
differential retention of tocopherols.  We further reported that HepG2 cells, a human 
hepatoblastoma cell line, and rat primary hepatocytes, are capable of synthesizing the 
carboxychromanol metabolites excreted in human urine (14, 15).  Here, using cell 
culture models, liver subcellular fractions, and a variety of cytochrome P450 (CYP) 
expression systems, we characterized an enzymatic pathway of tocopherol catabolism 
to their carboxychromanol metabolites.  This pathway involves the initial 
hydroxylation, catalyzed by CYP4F2, of a terminal methyl group of the phytyl tail, 
followed by stepwise removal of two- or three-carbon moieties, ultimately yielding the 
3’-carboxychromanol metabolite of the parent tocopherol.  Substrate specificity and 
inhibition studies suggest the physiological significance of this pathway in the 
regulation of tissue tocopherol status. 
 
Materials and Methods 
Tocopherols were purchased from Fluka Biochemicals, Milwaukee, WI (RRR-
γ-TOH) or ACROS Organics, Fisher Scientific, Pittsburgh, PA (RRR-α-TOH).  γ-
Tocotrienol was a gift from Rex Parker, Bristol-Meyers Squibb, Wallingford, CT.  β-
NADPH, β-NAD
+, and cytochrome P450 substrates and inhibitors were purchased  
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from Sigma Chemical Co, St. Louis, MO.  Sesamin was purchased from Cayman 
Chemical, Ann Arbor, MI.  Human liver microsomes, control insect cell microsomes, 
and insect cell microsomes expressing various human liver recombinant cytochrome 
P450 enzymes in combination with human recombinant cytochrome P450 reductase 
were purchased from BD-Gentest, Woburn, MA.  SV40 transformed human skin 
fibroblasts (GM0637) stably expressing CYP2E1, and sham-transfected control cells, 
were kindly provided by Paul Hollenberg, University of Michigan, Ann Arbor, MI. 
Cell Culture  
HepG2 cells (C3A subclone CRL-10741, American Type Culture Collection, 
Manassas, VA) were maintained in Minimal Essential Media (MEM; Atlanta 
Biologicals, Atlanta, GA) containing NaHCO3 and 10% fetal bovine serum (FBS-
Premium; Atlanta Biologicals, Atlanta, GA) without antibiotics under standard cell 
culture conditions.   
To prepare TOH-enriched media, an appropriate volume of RRR-γ-TOH, or 
RRR-α-TOH (12 mM solutions in ethanol), was added dropwise to FBS while mixing 
gently; the FBS was stored at 4
oC for a minimum of 4 hours, then diluted 1:10 with 
MEM.  Final tocopherol concentrations were 25-100 µM, and EtOH concentrations 
less than 0.85%. 
Experiments involving cytochrome P450 inhibitors were performed as 
described above with the following changes.  Stock solutions of various inhibitors in 
EtOH, were added drop-wise to complete media to a concentration of 1.0 µM.  Media 
was removed from confluent monolayers and replaced with inhibitor-containing 
media.  After a 4 hr preincubation period, this media was replaced with tocopherol-
enriched media containing the inhibitor, and then media and cells were collected after 
48 hr.  
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Suspensions of saline-washed cells were disrupted by sonication on ice, and an 
aliquot taken for protein quantification.  The remaining sample was stored at -20
oC 
under argon until analysis.  Protein was determined by the Bio-Rad method (Bio-Rad 
Laboratories, Hercules, CA) with bovine serum albumin (BSA) as the standard.   
Subcellular fraction preparation and incubation  
  Subcellular fractions were prepared by differential centrifugation from the liver 
of male CD rats sacrificed 3-5 hours after their last feeding (16).  Livers were minced 
in four volumes TES buffer (50 mM Tris/HCl, 5 mM EDTA, 0.25 M sucrose, pH 7.4) 
and homogenized with a Potter-Elveheim apparatus with teflon pestle. The 800 x g 
supernatant was centrifuged to obtain the 6,000 x g, 20,000 x g, and 100,000 x g 
pellets, representing the heavy mitochondrial, light mitochondrial-peroxisomal, and 
microsomal fractions, respectively.  Confluent HepG2/C3A cultures were processed 
into similar fractions. The fractions were subdivided in 100mM KH2PO4 buffer (pH 
7.4) and frozen at -80
oC until assayed for activity. 
The standard 1ml reaction system consisted of 100 mM KH2PO4 buffer (pH 
7.4) with 0.05-0.2 mg cell fraction protein, 0.5 mM NADPH, and with or without 0.5 
mM NAD
+.  Tocopherols were added as a complex with 1% BSA (Fraction V, Sigma) 
passed through a 0.22µ mixed cellulose ester filter.  Cytochrome P450 substrates or 
inhibitors were added as solutions in EtOH.  The reactions were pre-incubated at 37
oC 
for 10 min with vehicle or inhibitor and initiated by the addition of substrate or 
NADPH.  Reactions were terminated by the addition of 100 µl 3N HCl and 1 volume 
cold absolute ethanol.  
Cytochrome P450 inhibition and expression systems 
  Inhibition of tocopherol metabolism in HepG2 cell cultures and rat or human 
liver microsomal fractions was investigated using a variety of characterized P450 
inhibitors.  Positive controls for characterized P450 activities included testosterone 6β- 
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hydroxylation (CYP3A), 12- and 11-hydroxylation of lauric acid (CYP2E1, 4A), 7-
ethoxycoumarin de-ethylation (CYP2E1, 2B, 1A), and leukotriene B4 (LTB4) 20-ω-
hydroxylation (CYP4F2, 4F3A, 4F3B) (17-20).  Tocopherol metabolism was also 
investigated in fibroblasts stably expressing human liver CYP2E1 (21), and in insect 
microsomes selectively expressing various recombinant human CYP enzymes 
(CYP3A4, 3A7, 1A1, 2A6, 2B6, 2C19, 4A11, 4F2, 4F3A, 4F3B) or a combination of 
1A2, 2C8/9/19, 2D6, and 3A4 (Gentest, Woburn, MA), using reaction conditions as 
described above with modifications according to supplier recommendations.   
Metabolite Analyses  
For analysis of tocopherols and their metabolites in cell culture, media samples 
(3-10 ml) were acidified to pH 1.5 with 3N HCl and extracted with methyl-tert-butyl-
ether (MTBE).  As appropriate, custom-synthesized deuterium-labeled internal 
standards, d2-γ-CEHC (13) or d9-α-CEHC (the synthesis of which will be published 
separately) were added prior to acidification.  Sonicated cell pellet suspensions were 
acidified to pH 1.5 with 3N HCl, one volume cold absolute EtOH added, and the 
sample extracted twice with 8 ml hexanes.  Acidified subcellular fraction reaction 
samples were extracted with 9:1 hexanes:MTBE (TOH or lauric acid metabolites) or 
ethyl acetate (testosterone or 7-ethoxycoumarin metabolites) with d9α-TOH (22) 
added as an internal standard for TOH reactions and 17α-CH3-testosterone as an 
internal standard for testosterone reactions.  Solvents were removed under a stream of 
N2  and the residue silylated with pyridine and N,O-bis-[trimethylsilyl]-
trifluoroacetamide + 1%trimethylchrorosilane (BSTFA/ 1%TMCS; Pierce Chemical 
Co., Rockford, IL) under nitrogen at 70
oC for 30 min.  LTB4 reactions were stopped 
with 0.5 volumes of acetonitrile + 1% glacial acetic acid and centrifuged (10, 000 x g) 
for 3 minutes.    
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Preparation of tocopherol-loaded microsomes 
Isolated rat microsomes (0.05 mg protein) were incubated 30 min at 37
oC in 
1ml KH2PO4 buffer with various concentrations of an equimolar mixture of γ- and α-
TOH complexed with BSA.  Microsomes were re-isolated by centrifugation (100,000 
x g, 1 hour), washed with buffer and again re-isolated.  The microsomal pellet was 
resuspended in 1 mL buffer and extracted using a cold ETOH/Hexane extraction 
similar to the extractions described above, using d9α-TOH as internal standard.   
Extracts were silylated and analyzed by gas chromatography-mass spectrometry. 
Gas Chromatography-Mass Spectrometry (GC-MS) and HPLC 
A Hewlett Packard 6890 gas chromatograph, coupled to a Hewlett Packard 
5872 mass selective detector operated in either selected ion (SIM) or scan mode, was 
used for all analyses.  The GC was fitted with a Hewlett Packard HP-1 methylsiloxane 
capillary column (30 m X 0.25 mm) and operated in split injection mode using helium 
as the carrier gas.  For tocopherol metabolite analyses the oven was programmed to 
ramp from 200
oC (2 min hold) to 250
oC at 7
oC/min, followed by a 6 min hold at 
250
oC, then ramped to 280
oC at 25
oC/min, with a final hold at 280
oC for 9 min.   
Media concentrations of tocopherol metabolites were determined using the appropriate 
deuterated internal standards.  6β-hydroxy-testosterone, 12-hydroxy-lauric acid, and 7-
hydoxycoumarin were analyzed as above with minor changes in the oven temperature 
program.  LTB4 samples were assessed using the gradient reverse phase HPLC method 
of Shak (23). 
Catalytic Hydrogenation  
To ascertain the presence of double bonds in the metabolic intermediates, 
silylated media extracts from HepG2 cultures were dried under N2 gas and the residue 
reduced with palladium on carbon catalyst under H2 gas at 65
oC.  Samples were 
compared by GC-MS with and without hydrogenation.  
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Statistical Analysis 
Statistical analyses of enzyme activity data were performed using Microcal 
Origin 4.1 statistical software. 
 
Results 
Identification of intermediates of γ-tocopherol metabolism in HepG2 cultures 
Previously published mass spectra of γ-TOH and it’s 3’-carboxychromanol (γ-
CEHC) and 5’-carboxychromanol (γ-CMBHC) metabolites all exhibit a base peak at 
m/z 223, reflecting a common fragmentation pattern of the γ-chroman-O-trimethylsilyl 
(TMS) ring moiety (11, 14).  GC-MS analyses of extracts of media from HepG2 cells 
incubated in the presence of 50 µM γ-TOH revealed several substances not present in 
extracts of control cultures and which exhibited a base peak at m/z 223.  Figure 2.1 
illustrates a typical ion chromatogram of a media extract using the selected ion 
monitoring (SIM) mode monitoring m/z 223.  Peaks labeled with roman numerals 
occurred only in samples from cells incubated with γ-TOH.  Peaks I, II, and V 
correspond to the di-TMS derivatives of the 3’-carboxychromanol (γ-CEHC) and 5’-
carboxychromanol (γ-CMBHC) metabolites of γ-TOH, and to the TMS derivative of 
γ-TOH respectively, as evidenced by their mass spectra and by comparison of 
retention times to synthetic di-TMS-γ-CEHC or TMS-γ-TOH.   
The mass spectra of peaks III, IV, and VI of Figure 2.1 are shown in Figure 
2.2.  These spectra all exhibited strong base peaks at m/z 223, the expected molecular 
ions, and other characteristics consistent with the structures of the di-TMS derivatives 
of the 7’-, 9’-, and 11’-carboxychromanol metabolites of γ-TOH, respectively, as 
illustrated in Figure 2.5.   
Peaks III and VI, identified as 7’- and 11’-γ-carboxychromanols respectively, 
were each consistently accompanied by two minor peaks exhibiting base ions at m/z  
 
 
60 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 
GC-MS (EI) chromatogram of extracts of HepG2 cultures incubated with 50 µM γ-
TOH, obtained using selected ion (SIM) analysis of the major γ-chroman ring 
fragment, m/z 223.  Peaks corresponding to γ-TOH and its metabolites are labeled 
with roman numerals I-VIII. 
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Figure 2.2 
Mass spectra (EI) of peaks III, IV, and VI of the chromatogram shown in Figure 2.1, 
interpreted as the TMS derivatives of the 7’-, 9’-, and 11’-γ-carboxychromanol 
metabolites of γ-TOH, respectively. 
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223 but molecular ions two mass units less than their respective major peak (peaks 
III* and VI*, Figure 2.3A, B).  Extracts were compared before and after catalytic 
hydrogenation.  Hydrogenation was accompanied by the disappearance of peaks III* 
and VI*, with a corresponding increase in the relative abundance of Peaks III and VI 
(Figure 2.3C, D).  While the position of the double bond along the phytyl tail is yet to 
be determined, based on the analogy to fatty acid β-oxidation, the putative unsaturated 
analogs were assigned the structures of III* and VI* in Figure 2.5. 
The mass spectra of peaks VII and VIII, eluting at 22.7 min and 24.5 min 
respectively (Figure 2.1), are presented in Figure 2.4.  These were the only 
metabolites common to both HepG2 cell cultures and rat liver subcellular reaction 
systems.  Peak VII exhibited a molecular ion at m/z 576 and m/z 103 (-CH2-O-TMS), 
consistent with a metabolite possessing an intact γ-chromanol ring and a hydroxylated, 
but otherwise full-length, phytyl side chain.  Peak VIII exhibited a molecular ion at 
m/z 590 and other features consistent with a di-TMS derivative of γ-TOH possessing 
an intact γ-chromanol ring, a carboxylic acid moiety and a full-length phytyl side 
chain.  Consistent with the presence of the 11’-carboxychromanol intermediate (VI) 
and the absence of other hydroxylated intermediates, peaks VII and VIII were 
assigned the structures of the terminal hydroxy and carboxy analogs of γ-TOH, and as 
illustrated in Figure 2.5, and designated 13’-hydroxytocopherol (13’-OH-TOH) and 
13’-carboxytocopherol (13’-COOH-TOH).  Relative to media extracts, cell extracts 
were consistently enriched in the longer, more hydrophobic metabolites, particularly 
the hydroxychromanol metabolite (VII).  Due to the normally attenuated metabolism 
of α-TOH by HepG2 cells (14), the terminal hydroxy and carboxy metabolites of α-
TOH were not detected in these cultures but were consistently present in rat liver 
subcellular fractions incubated with α-TOH.  The expected unsaturated metabolites of  
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Figure 2.3 
Mass spectra (EI) of peaks labeled as III* (panel A) and VI* (panel B) of the 
chromatogram shown in Figure 2.1.  Panel C: SIM chromatogram, monitoring the 
indicated ions, of one half of a 50 µM γ-TOH HepG2 culture extract prior to catalytic 
hydrogenation.  Panel D:  SIM chromatogram of the remainder of the extract 
following catalytic hydrogenation, illustrating the absence of peaks III* and VI*, 
interpreted to represent TMS derivatives of unsaturated β-oxidation intermediates of 
the 7’- and 11’-γ-carboxychromanol metabolites of γ-TOH. 
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Figure 2.4 
Mass spectra (EI) of peaks VII and VIII of the chromatogram shown in Figure 2.1, 
interpreted as the TMS derivatives of the terminal 13’-hydroxy (13’-OH-TOH) and 
13’-carboxy (13’-COOH-TOH) metabolites of γ-TOH, respectively. 
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Figure 2.5 
Pathway of metabolism of γ-TOH to its 3’-γ-carboxychromanol metabolite, based on 
identification of intermediates from HepG2 cultures incubated with 50µM γ-TOH.  
Roman numerals correspond to those of Figures 2.1-2.4. 
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γ-tocotrienol were observed in the hepatocyte cultures (data not shown), suggesting 
that tocopherols and tocotrienols are metabolized via this pathway. 
To test the hypothesis that the initial steps in tocopherol side-chain metabolism 
consist of a cytochrome P450 (CYP)-mediated ω-hydroxylation followed by 
dehydrogenation to the carboxylic acid, time course reactions with either γ- or α-TOH 
as substrates were carried out in rat liver microsomes. Synthesis of the 13’-OH-TOH 
and 13’-COOH-TOH metabolites was observed for both tocopherols in the presence of 
NADPH but not in its absence.  With 0.5 mM NADPH as the only cofactor added, 
accumulation of the carboxylated metabolite occurred subsequent to that of the 
hydroxylated metabolite, particularly for γ-TOH, suggestive of a precursor-product 
relationship (Figure 2.6).  Additionally, when 0.5 mM NAD
+ was also included, the 
hydroxylated metabolite accumulated only during the initial stage of the reaction, but 
was relatively suppressed thereafter.  Conversely, NAD
+ stimulated accumulation of 
the carboxylated metabolite to levels above those observed for the hydroxylated 
metabolite in the absence of NAD
+.  Throughout the course of the reaction (80 
minutes) metabolism of γ-TOH (Figure 2.6, panel A) in the rat liver microsomes was 
between five- and ten-fold greater than that of α-TOH (Figure 2.6, panel B). 
Involvement of Cytochrome P450 4F2 in the ω-hydroxylation of tocopherols                            
The identification of a terminally hydroxylated metabolite of γ-TOH and α-
TOH upon the incubation of rat liver microsomes with NADPH suggested a role for 
one or more P450 mono-oxygenases in the initiation of side chain truncation of 
tocopherols.  In an effort to determine which CYP isoform(s) might be involved, a 
variety of CYP expression and inhibition systems were employed.  We earlier reported 
a striking inhibition of γ-TOH metabolism by 1 µM ketoconazole in both HepG2 cells 
and rat primary hepatocytes and by 1 µM sesamin, a sesame seed lignan, in HepG2 
cells (15).  More recent findings have shown that ketoconazole and sesamin (1 µM)  
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Figure 2.6 
Time course of synthesis of the 13’-OH-TOH and 13’-COOH-TOH metabolites of γ-
TOH (panel A) and α-TOH (panel B) in rat liver microsomes incubated with 25 µM 
tocopherol as a BSA complex, 0.5 mM NADPH and with or without the addition of 
0.5 mM NAD
+.  Note the difference (10X) in scale of the Y-axis between panels A 
and B.  Data (representative experiment) are means and standard deviations of 
triplicate analyses at each time point. 
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both potently inhibit (>80%) γ- and α-TOH metabolism in hepatocyte cell culture 
(data not shown).  Inhibition by either substance was not accompanied by increases in 
any intermediate, indicative of inhibition at the initial oxidation step of the pathway.  
Based on the reported specificity of ketoconazole for CYP3A at this low concentration 
(24), we originally proposed a role for CYP3A in tocopherol catabolism (15).   
However, in the present study both control insect microsomes expressing no human 
P450 enzymes and insect microsomes expressing active recombinant human CYP3A4 
or CYP3A7 failed to produce any of the tocopherol metabolites identified from 
HepG2 cultures or rat liver subcellular fractions.  Furthermore, testosterone-6β-
hydroxylase activity in these microsomes or in rat liver microsomes, while strongly 
inhibitable by ketoconazole, was not inhibitable by sesamin, a potent inhibitor of 
tocopherol metabolism.  These findings demonstrate that CYP3A does not possess 
tocopherol-ω-hydroxylase activity.  Subsequent investigation showed that insect 
microsomes expressing other major human liver CYP enzymes (CYP1A1/2, 
CYP2C8/9/19, 2A6, 2B6, 2D6, 4A11) likewise exhibited no appreciable activity 
toward either γ- or α-TOH.  Additionally, GM-2E1 fibroblasts stably expressing 
recombinant human CYP2E1 (21), while actively carrying out O-de-ethylation of 7-
ethoxycoumarin, did not metabolize γ-TOH to any identified metabolite (not shown).  
In contrast, insect microsomes expressing recombinant human liver CYP4F2 exhibited 
clear NADPH-dependent ω-oxidation of γ- and α-TOH to their terminally 
hydroxylated and carboxylated metabolites.  Insect microsomes expressing 
recombinant human liver CYP4F3B also contained tocopherol-ω-hydroxylase activity, 
but at levels less than 1% that of CYP4F2.  Those expressing human neutrophil 
CYP4F3A exhibited no activity toward the tocopherols.  All three CYP4F isoforms 
actively catalyzed the 20-ω-hydroxylation of LTB4 (data not shown).  Tocopherol-ω- 
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hydroxylase activity was also observed in rat kidney homogenates and microsomes 
(data not shown), consistent with the expression of CYP4F2 in kidney tissue (25). 
The extent of discrimination between γ- and α-TOH  ω-hydroxylation 
demonstrated in rat liver was compared to that in human liver microsomes and insect 
microsomes expressing recombinant human CYP4F2.  As illustrated in Figure 2.7, all 
three microsomal systems exhibited marked substrate preference for γ-TOH when 
incubated with both tocopherols under initial velocity conditions.  Rat liver 
microsomes, which contain CYP4F1, a P450 isoform closely related to human 
CYP4F2 (26), exhibited over four-fold greater activity toward both tocopherols when 
compared with the human microsomal preparation.  Rat and human liver microsomes 
showed greater discrimination between the two tocopherols than the insect 
microsomes containing expressed CYP4F2.  In all cases metabolism of both γ- and α-
TOH was significantly inhibited (80-100%) by 1 µM sesamin (Figure 2.7). 
The observed difference in tocopherol-ω-hydroxylase activity toward γ- and α-
TOH in both separate (Figure 2.6) and mixed (Figure 2.7) substrate incubation 
conditions was further investigated through the determination of the kinetic constants 
for the rat liver microsomal reaction and the recombinant human CYP4F2 reaction.  
Under initial velocity conditions, rat liver microsomes (Figure 2.8, left panel) 
exhibited roughly similar Km values (68 and 42 µM) for γ- and α-TOH, respectively, 
but a nearly 6-fold greater Vmax for γ-TOH vs. α-TOH (0.73 vs. 0.13 nmol/mg 
protein/min, respectively).  Recombinant human CYP4F2 (Figure 2.8, right panel) 
likewise exhibited similar Km values of 37 and 21 µM for γ- and α-TOH, 
respectively, while having a Vmax for γ-TOH much greater than that for α-TOH (1.99 
vs. 0.16 nmol/nmol P450/min, respectively).  Hyperbolic regression analysis revealed 
simple Michaelis-Menten kinetics for the microsomal systems with both tocopherols 
regardless of whether they were presented singly or combined.  
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Figure 2.7 
Substrate discrimination in synthesis of metabolites of γ- and α-TOH by rat or human 
liver microsomes (0.01 mg protein/reaction; left Y-axis), and insect cell microsomes 
expressing recombinant human liver CYP4F2 (15 pmol P450/reaction; right Y-axis).  
Also shown is the inhibitory effect of 1 µM sesamin on synthesis of the metabolites of 
γ- and α-TOH in each microsomal system.  Bars represent the sum of concentrations 
of the 13’-OH-TOH and 13’-COOH-TOH metabolites of each tocopherol after 20 
minute incubation with an equimolar BSA complex mixture of 50 µM γ-TOH plus 50 
µM α-TOH, along with 0.5 mM NADPH, and 0.5 mM NAD
+.  “n.d.”, not detected.  
Data (representative experiment) are means and standard deviations of triplicate 
analyses. 
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Figure 2.8 
Kinetic analysis of formation of metabolites of γ- and α-TOH by rat liver microsomes 
(0.05 mg protein/reaction; panel A) and by insect microsomes expressing recombinant 
human CYP4F2 (0.015 nmol P450/reaction; panel B) over a range (10-200 µM, rat or 
25-125 µM, CYP4F2) of tocopherol concentrations during a 20 minute incubation 
with 0.5 mM NADPH and 0.5 mM NAD
+.  Tocopherols were added to separate 
reactions in a BSA complex as described in Experimental Procedures.  Total 
metabolite represents the sum of 13’-OH-TOH and 13’-COOH-TOH metabolites.   
Data (representative experiment) presented as scatter plot of means and standard 
deviations of triplicate analyses at each TOH concentration overlayed with best fit 
hyperbolic curve as determined by non-linear regression analysis and defined by 
goodness-of-fit χ
2 minimization.  Apparent Km and Vmax values were determined 
from resulting hyperbolic equation.  Rat liver microsomes: γ-TOH; Km = 68 µM, 
Vmax = 0.73 nmol/mg/min, χ
2 = 0.00128.  α-TOH; Km = 42 µM, Vmax = 0.13 
nmol/mg/min, χ
2 = 0.00006.  CYP4F2 microsomes: γ-TOH; Km = 37 µM, Vmax = 
1.99 nmol/nmol P450/min, χ
2 = 0.00061.  α-TOH; Km = 21 µM, Vmax = 0.16 
nmol/nmol P450/min, χ
2 = 0.00021. 
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To assess the extent of association of the tocopherols with the microsomes 
during a typical reaction, rat liver microsomes were incubated with varying 
concentrations of an equimolar mixture of γ- and α-TOH (BSA complex) as described 
in the Experimental Procedures.  Membrane tocopherol association was similar for 
both tocopherols and increased linearly throughout the substrate concentrations tested 
(25-200  µM each TOH).   Baseline (endogenous) concentrations of α-TOH were 
nearly 3-fold higher than those of γ-TOH (0.29 +/- 0.01 vs. 0.11 +/- 0.08 nmol/mg 
protein, respectively), and both increased markedly to 219 +/- 9 nmol/mg protein after 
a 30 min incubation with 25µM tocopherol-BSA complex. 
 
Discussion 
The objective of this study was to elucidate the pathway by which tocopherols 
are metabolized to their side chain truncated, water-soluble carboxychromanol 
metabolites excreted in human urine, and to determine whether such a pathway 
exhibits specificity among the common tocopherol vitamers.  Here we present direct 
evidence from several experimental systems for the expected intermediates in a 
pathway involving terminal ω-hydroxylation of the tocopherol phytyl side chain, 
oxidation to the corresponding terminal carboxylic acid, and sequential removal of 
three- or two-carbon moieties by β-oxidation ultimately yielding a water-soluble 3’-
carboxychromanol.  This represents the first characterized enzymatic pathway of 
tocopherol biotransformation in mammalian tissues. 
We additionally provide evidence for the involvement of the cytochrome P450 
isoform 4F2 in the initial ω-hydroxylation of both γ- and α- tocopherol and for its 
catabolic discrimination between these two tocopherols.  This isoform was the only 
major human liver P450 isoform tested which exhibited appreciable tocopherol-ω-
hydroxylase activity.  This finding does not exclude the possibility that other minor  
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P450 enzymes may exhibit such activity.  Human liver microsomes exhibited a higher 
degree of discrimination between the two tocopherols than insect microsomes 
expressing only recombinant human CYP4F2 (Figure 2.7).  This may indicate the 
presence of other P450 enzymes in human liver that contribute to the observed 
discrimination.  However, a considerable specificity of the activity was indicated by 
the fact that two other recombinant human CYP4F isoforms closely related to 
CYP4F2, namely 4F3A and 4F3B (20), exhibited little or no tocopherol-ω-
hydroxylase activity while all three enzymes catalyzed the 20-ω-hydroxylation of 
LTB4.  Kinetic analyses of the tocopherol-ω-hydroxylase activity in the rat liver 
microsomal system and recombinant human CYP4F2 microsomal system revealed 
similar Km but notably different Vmax for γ- and α-TOH, with the catalytic activity 
several fold higher for γ-TOH, regardless of whether the substrates were presented 
singly or in combination.  Comparison of the determined kinetic constants with 
hepatic tocopherol concentrations is not straightforward as the latter is dynamic and 
exists in several pools.  These include tocopherols associated with membranes, lipid 
droplets or vesicles, and with cytosolic proteins such as tocopherol transfer protein 
(TTP).  The relevance of each to the enzyme activity characterized here is not yet 
clear.  Hepatic cytosolic and membrane concentrations have been reported at 0.005 
and 0.2-0.4 nmol/mg protein, respectively (27, 28), the latter of which agrees with the 
endogenous microsomal tocopherol concentrations reported here.  Incubation of 
microsomes with 25 µM tocopherol-BSA, i.e. near the apparent Km, yielded 
microsomal tocopherol levels of approximately 219 nmol/mg protein, or three orders 
of magnitude above the endogenous level.  Thus, although in vivo hepatic tocopherol 
concentrations probably fluctuate considerably with feeding state, membrane 
concentrations are most likely well below the Km for the tocopherol-ω-hydroxylase 
which is therefore never saturated.  
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Two lines of evidence indicate that the tocopherol-ω-hydroxylase pathway 
described here is of physiological importance in the post-absorptive regulation of 
tocopherol status in vivo, in particular the preferential retention of α-TOH relative to 
other tocopherols.  First, in humans a substantial proportion of estimated daily intake 
of γ-TOH, but not of α-TOH, undergoes urinary excretion as its 3’-carboxychromanol 
(13), the major product of this catabolic pathway.  This observation is consistent with 
the greater tocopherol-ω-hydroxylase activity exhibited toward γ-TOH than α-TOH 
reported here.  Secondly, administration of sesame oil or purified sesamin results in 
elevated tocopherol concentrations in rats and humans, with the effect greater toward 
γ-TOH (29-31).  We have demonstrated here and in a previous report (15) that 
sesamin is a potent inhibitor of tocopherol-ω-hydroxylase activity exhibited by 
hepatocyte cultures, rat and human liver microsomes, and recombinantly expressed 
human liver CYP4F2.  Taken together, the in vivo and in vitro evidence strongly 
indicate that the tocopherol-ω-hydroxylase pathway is a physiologically important 
mechanism in the regulation of vitamin E status. 
To date, only one other protein, the hepatic tocopherol transfer protein (TTP), 
has been implicated in the regulation of vitamin E status in vivo, and to exhibit 
selectivity toward α-TOH (8, 9, 32).  TTP has been proposed to facilitate the selective 
secretion of α-TOH from liver into the bloodstream via very low-density lipoproteins 
(8), and may modulate intracellular tocopherol-ω-hydroxylase substrate concentrations 
in the liver, but such an interaction remains to be demonstrated.   
The involvement of CYP4F2 in tocopherol catabolism is of potential 
physiological significance.  As mentioned, CYP4F2 catalyzes the ω-hydroxylation of 
leukotriene B4 (LTB4) to 20-OH-LTB4, a metabolite with considerably less 
chemotactic activity (19).  In addition, CYP4F2 ω-hydroxylates arachidonic acid to 
20-OH-arachidonic acid, a metabolite proposed to play critical roles in kidney  
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function, including vascular tone and natriuresis (33).  The reported Km values for 
arachidonic acid (24 µM) and LTB4 (45 µM) are similar to those reported here for γ- 
and  α-TOH (25, 34).  Whether some or all tocopherols, from dietary sources or 
supplements, can influence physiological phenomena involving CYP4F2-dependent 
leukotriene or arachidonic acid metabolism clearly merits investigation. 
The extent to which carboxychromanol metabolites of tocopherols exhibit 
important biological effects in vivo remains uncertain.  With an intact chromanol 
moiety, these metabolites could in principle participate in radical trapping reactions in 
the aqueous milieu of tissues and plasma.  However, these metabolites are excreted in 
urine largely, if not entirely, as glucuronide conjugates (13), and a large proportion of 
the plasma pool of these metabolites likewise appears to be conjugated (35).  While 
the nature of the conjugated forms of these metabolites has not been characterized, 
conjugation at the phenolic hydroxyl group would effectively abolish antioxidant 
activity.  Tocopherol metabolites may also exhibit biological activities apart from their 
radical quenching abilities.  The 3’-γ-carboxychromanol metabolite of γ-TOH was first 
reported as a natriuretic factor (11), and more recently as an inhibitor of prostaglandin 
E2 synthesis (36). 
In summary, we describe a novel CYP4F2-mediated tocopherol-ω-hydroxylase 
pathway of metabolism of tocopherols to water-soluble carboxychromans that are 
excreted in urine.  This pathway preferentially metabolizes γ-TOH over α-TOH, and 
inhibition studies, both in vitro and in vivo, indicate its importance in the regulation of 
tissue tocopherol concentrations.  Differential rates of catabolism of tocopherols via 
this pathway may well prove to underlie the large differences in their bioactivity that 
do not appear to be explained by their intrinsic radical trapping properties (37-39).    
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CHAPTER III 
 
COMPARATIVE INFLUENCE OF MAJOR 
STRUCTURAL FEATURES OF TOCOPHEROLS AND 
TOCOTRIENOLS IN THE KINETICS OF ω-OXIDATION 
BY CELLULAR AND MICROSOMAL TOCOPHEROL-ω-
HYDROXYLASE  
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Abstract 
Differential catabolism (ω-hydroxylation/β-oxidation) of the tocochromanol 
vitamers making up the vitamin E family of molecules is one of the major factors 
determining vitamin E status, as evidenced by studies using inhibitors of this catabolic 
pathway.  We previously demonstrated that tocopherol-ω-hydroxylase (cytochrome 
P450 CYP4F2) is responsible for the initiation of this pathway.  Here, we characterize 
the activity of this enzyme and the influence of key structural features of the vitamin E 
substrates on its activity.  The influence of extent and position of methylation around 
the chromanol ring, and of stereochemistry and degree of saturation of the phytyl side-
chain, were explored using hepatocytes and various microsomal enzyme systems.  In 
HepG2 cells methylation at carbon 5 of the chromanol ring was inhibitory toward ω-
oxidation, while methylation at carbons 7 or 8 was less influential.  There was no 
significant effect of side-chain stereochemistry on metabolism of tocopherols to their 
3’and 5’-carboxychromanols.  The tocotrienols were metabolized to a much greater 
extent than their corresponding tocopherols.  Structure-specific effects similar to those 
seen in cell culture were observed for tocopherol-ω-hydroxylase activity by rat and 
human liver microsomes, as well as in microsomes from insect cells selectively 
expressing CYP4F2.  Substrate access to the enzyme was a strong determinant of 
metabolic rates, as the tocotrienols were incorporated into cell and microsomal 
membrane to a greater extent than the tocopherols.  Kinetic parameters Vmax and 
apparent Km were determined for the tocopherol-ω-hydroxylase toward each 
substrate, revealing allosterism by the enzyme toward most vitamers, especially the 
tocotrienols, but normal Michaelis-Menten kinetics when α-TOH was the substrate.  
Substrate competition experiments revealed α-tocopherol acted as a positive effector 
toward the substrates displaying allosteric metabolism, increasing the Vmax of the 
enzyme toward these substrates.  In vivo supplementation of α-tocopherol is  
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suppresses the plasma levels of the other vitamers, and our data suggest for the first 
time an enzymatic mechanism explaining this phenomenon.   Taken together, these 
results support the contention that CYP4F2-mediated tocopherol-ω-hydroxylation is a 
highly specific mechanism underlying the different biological half-lives, and therefore 
biopotency, of the vitamin E vitamers.  
 
Introduction 
Vitamin E is the generic name for a group of lipid soluble molecules made up 
of the tocopherols and tocotrienols, some of which are more biologically active than 
others (1).  These molecules differ in the number and position of methyl groups 
around the chromanol ring, as well as in the saturation and stereochemistry of the 
phytyl tail (Figure 3.1).  These slight structural variations appear to play a strong role 
in the biological activity of the different vitamers.   
Until recently, the term Vitamin E was generally associated with α-tocopherol, 
the most abundant form of vitamin E found in human plasma and tissues, which has 
led to this vitamer being the focus of many E-related studies.  Current research is 
pointing toward many important roles for the non-α vitamers of vitamin E, roles 
distinct from those of α-tocopherol and based on the minor structural differences 
between the various vitamers.   
Vitamin E function has been most closely associated with its ability to act as a 
lipid-soluble anti-oxidant.  The antioxidant activity of individual vitamers appears to 
be highly dependent on their structural features with α-TOH being the most effective 
of the tocopherols in vivo (2,3), a feature which largely disappears under conditions 
where plasma and tissue levels of other vitamers are similar to those of α-TOH (4).  
The tocotrienols appear to posses even greater antioxidant activity in lipid membranes 
than their corresponding tocopherols (5).  However, similar antioxidant activity has  
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R1 R2 R3 
Tri-methyl  α  CH3 CH3 CH3 
Di-methyl  γ  H  CH3 CH3 
Di-methyl  β  CH3  H  CH3 
Di-methyl  ε  CH3 CH3  H 
Mono-methyl  δ  H H  CH3 
No-methyl  tocol  H H H 
 
Tocopherol = no double bonds on phytyl tail 
All rac = racemization at carbons 2, 4’, and 8’ 
Tocotrienol = double bonds at carbons 3’-4’, 7’-8’, and 11’-12’ 
Figure 3.1 
Vitamin E structure depicting variations in vitamer structural features.  
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been found in selenium-deficient cells, once differences in vitamer uptake into the 
cells had been accounted for (6).  Vitamer specific functions have been demonstrated 
apart from their radical trapping ability.  α-TOH has been shown to be an effective 
inhibitor of PKC activity, smooth muscle cell growth, and nitric oxide production, as 
well as being implicated in the regulation of gene transcription (7-10).  γ-TOH, due to 
its lack of a methyl group in the C-5 position, is better than α-TOH at trapping 
reactive nitrogen oxide species (11,12).  Additionally, γ-TOH possesses anti-
inflammatory activity which is not found for α-TOH (13).  Several studies have 
reported an inverse correlation between plasma γ-TOH levels and cardiovascular 
disease while this same correlation was not observed for α-TOH (14).  The 
tocotrienols appear to act as inducers of apoptosis in certain cell types to a far greater 
degree than their tocopherol counterparts (15-17).  The tocotrienols also have 
demonstrated hypocholesterolemic properties in rats which is attributed their vitamer-
specific ability to act as inhibitors of HMG-CoA Reductase (18).   
The superior activity of α-TOH in vivo appears to result from its superior 
retention in the body relative to other vitamers [i.e. the body selectively retains only 
the natural RRR form of α-TOH while eliminating the other vitamers] (19).  There 
appear to be several mechanisms underlying this selectivity.  One mechanism involves 
the tocopherol transfer protein α-TTP.  This protein displays a strong binding affinity 
for  α-TOH which aids in the hepatic packaging of α-TOH for distribution to 
extrahepatic tissues (20,21).  Non-α vitamers as well as the synthetic racemic α-TOH 
show poor affinity for α-TTP and are rapidly metabolized and excreted into the urine 
(22,23).   
In addition to the preferential retention of α-TOH relative to the other 
vitamers, α-TOH itself appears to facilitate the elimination of the non-α vitamers.  
Several in vivo studies have reported a decrease in plasma concentrations of the non-α  
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tocopherols upon supplementation with α-TOH, although the mechanism behind this 
phenomenon has remained largely unknown (24,25).   
The pathway of metabolism of the tocopherols to water soluble metabolites 
appears itself to be a second important mechanism of discrimination between the 
vitamers.  The tocopherols and tocotrienols are metabolized to water soluble urinary 
metabolites with the side chain shortened to the 3’-carbon (26-30).  Our lab has shown 
that this takes place by means of an initial ω-hydroxylation at a terminal methyl group 
of the phytyl tail, followed by sequential β-oxidation to the 3’ carboxychromanol 
metabolite (CEHC).  The intermediates in this pathway have been identified for both 
the tocopherols and tocotrienols (31,32).  The initial ω-hydroxylation step in this 
pathway has been demonstrated by our lab to be catalyzed by a member of the 
cytochrome P450 family of enzymes, CYP4F2, and is an important regulator of 
vitamer status in vivo.  The inhibition of tocopherol-ω-hydroxylation by sesame 
lignans in rats has been shown to increase the plasma levels of γ-TOH to levels 
approaching those of α-TOH (4).   CYP4F2 is a member of the CYP4F family of P450 
enzymes which were originally found to carry out the ω-oxidation of leukotriene B4 
and arachidonic acid (33,34).  Kinetic analysis of the activity of the major isoforms of 
CYP4F, hepatic 4F2 and 4F3A, and neutrophil 4F3B, reveals CYP4F2 has the lowest 
activity toward LTB4 (35,36) while activity of the CYP4F toward vitamin E is only 
present in appreciable amounts in the 4F2 isoform (31).  This activity is several fold 
greater toward γ-TOH than α-TOH.  Given the wide range of structural variations 
among the substrates that individual P450 enzymes can metabolize, it is surprising to 
find the presence of one methyl group on α-TOH can so greatly attenuate the activity 
of the CYP4F2 enzyme when compared to γ-TOH.  These findings suggest not only 
substrate specificity for vitamin E relative to the other CYP4F2 substrates, but also a  
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strong vitamer preference by the enzyme based on intramolecular variations within the 
vitamin structure.   
We here investigated the effects of structural variations among the vitamers of 
vitamin E on the activity of the tocopherol-ω-hydroxylase enzyme. The effects of 
methylation, stereochemistry, and phytyl tail unsaturation on vitamin E catabolism are 
demonstrated in both cell culture and microsomal models.  Kinetic analysis of the 
tocopherol-ω-hydroxylase activity revealed allosteric effects within the enzyme-
substrate interactions.  α-Tocopherol acted as a positive effector, increasing the ω-
hydroxylation of the non-α vitamers.  Lastly, we propose a role for tocopherol-ω-
hydroxylase in mediating the suppression effect of α-TOH on levels of other 
tocopherols in vivo. 
 
Materials and Methods 
Tocopherols were purchased from Fluka Biochemicals, Milwaukee, WI (RRR-
γ-TOH), ACROS Organics, Fisher Scientific, Pittsburgh,  PA (RRR-α-TOH), or 
Matreya Inc. (Rac-α-, γ-, β-, ε-TOH, and tocol (τ).  The tocotrienols were a gift from 
Volker Berl, BASF, Ludvigshafen, Germany.  β-NADPH and NAD were purchased 
from Sigma Chemical Co, St. Louis, MO.  Pooled human liver microsomes and insect 
microsomes expressing various human liver cDNA Cytochrome P450s in combination 
with human cDNA P450 Reductase were purchased from Gentest, Inc., Woburn, MA.  
Rat liver microsomes were prepared as described previously (31). 
Cell Culture  
HepG2 cells (C3A subclone CRL-10741, American Type Culture Collection, 
Manassas, VA) were maintained in Debubelco’s Minimal Essential Media (DMEM) 
containing NaHCO3 and 10% fetal bovine serum (FBS, USDA Certified; Mediatech, 
Inc, Herndon, VA) and without antibiotics under standard cell culture conditions.    
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TOH-enriched media was prepared using an appropriate volume of each TOH 
(5-30 mM solution in ethanol) added drop-wise to FBS while mixing gently. The FBS 
was stored at 4
oC for a minimum of 4 hours, then diluted 1:10 with DMEM.  Final 
tocopherol concentrations were 25 µM, and EtOH concentrations were less than 
0.85%.  After 0-48 hour incubations with cells, the media was collected and cells were 
washed and scraped into 0.9% NaCl.  Media and cells were stored at -20
oC under 
argon until analyzed. 
Microsomal Metabolism System 
The microsomal reaction system consisted of 100 mM KH2PO4 buffer (pH 7.4) 
with 100 mg/ml pooled human or rat liver microsomes, or 20 pmol/ml CYP4F2 insect 
cell microsomes, and 0.5-1.0 mM NADPH + NAD.  Tocopherols were added as a 
complex with 1% (w/v) Fraction V bovine serum albumin (BSA) as described 
previously (31).  Microsomes were pre-incubated with the TOH-BSA complex at 37
oC 
for 60 min to allow substrate to associate with membrane.  TOH metabolite reactions 
were initiated with the addition of NADPH + NAD either in the presence of any 
remaining exogenous TOH-BSA immediately following the pre-incubations, or after 
centrifugal isolation of the TOH-loaded membranes to eliminate any unbound TOH-
BSA.  TOH-loaded membranes were isolated by centrifugation for 1 hr at 100,000 x g, 
washed and resuspended in reaction buffer.  Reactions were carried out for 0-40min at 
37
oC and terminated by the addition of 100 µl 3N HCl and 2 volumes cold absolute 
ethanol.  
Metabolite Analyses  
For the analysis of short chain metabolites in cell culture, custom-synthesized 
deuterium labeled d9-α-CEHC was added to media samples (3 ml) which were then 
acidified to pH 1.5 with 3N HCl and extracted with ethyl acetate.  Cell pellet 
suspensions were sonicated, acidified to pH 1.5 with 3N HCl, and precipitated with 2  
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volumes of cold absolute ethanol.  Long chain metabolites and the parent tocopherol 
or tocotrienol were extracted from both cell suspensions and metabolite reaction with 
1 volume methyl-tert-butyl-ether and 8 volumes hexane following the addition of 
deuterium labeled d9α-TOH as internal standard.  Solvents were removed under a 
stream of N2  and the residue silylated with pyridine and N,O-bis-[Trimethylsilyl]-
trifluoroacetamide containing 1%Trimethylchrorosilane (BSTFA + 1%TMCS) (Pierce 
Chemical Co., Rockford, IL) under N2 at 70
oC for 30 min.   
Gas Chromatography-Mass Spectrometry (GC-MS) 
A Hewlett Packard 6890 gas chromatograph, coupled to a Hewlett Packard 
5872 mass selective detector operated in either selected ion (SIM) or scan mode, was 
used for all analyses.  The GC was fitted with a Hewlett Packard HP-1 methylsiloxane 
capillary column (30 m X 0.25 mm) and operated in split injection mode using helium 
as the carrier gas.  For short-chain tocopherol metabolite analyses the oven was 
programmed to ramp from 200
oC (2 min hold) to 250
oC at 7
oC/min, followed by a 6 
min hold at 250
oC, then ramped to 280
oC at 25
oC/min, with a final hold at 280
oC for 9 
min.  Long chain metabolite and parent tocopherols were analyzed with the oven set at 
280
oC for 10 min. Tocopherol and metabolite concentrations were determined using 
the appropriate deuterated internal standards.  Cell- and microsome-associated vitamer 
are expressed on a per cholesterol basis, as cholesterol content is a good standard for 
total membrane mass.   
Kinetic analysis  
Kinetic constants were obtained using OriginLab Origin 7 software.  Kinetic 
data were analyzed using a non-linear curve fit method included in the software to 
yield a best fit line and error values. 
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Results 
The comparative metabolism of the various forms of vitamin E were examined 
in hepatocyte culture and in various microsomal systems, including human liver 
microsomes and microsomes from insect cells in which recombinant human 
cytochrome P450 tocopherol-ω-hydroxylase (CYP4F2) had been selectively 
expressed.  Total flux through the ω-hydroxylation/β-oxidation pathway was 
expressed as the sum of the metabolites produced over the course of the experiment.  
Rates of metabolism of the vitamers were compared based on four features of the 
tocochromanol molecule depicted in Figure 3.1: (a) extent of methylation of the 
chromanol ring (α-, γ-, δ-TOH, and Tocol, which contain 3, 2, 1, and 0 methyl groups 
respectively), (b) position of these methyl groups, focusing on the dimethyl 
tocopherols (γ-,  β-,  ε-TOH, which lack a methyl group at positions 5, 7, and 8 
respectively), (c) racemerization of the phytyl tail (RRR- vs. all-rac α- and γ-TOH), 
and (d) saturation of the phytyl tail (α-, γ-, δ-TOH vs. α-, γ-, δ-T3). 
Vitamer Metabolism in Hepatocyte Cell Culture 
HepG2/C3A hepatocytes were incubated with equimolar amounts of each of 
the 11 structurally different vitamers for 48 hours, and the generation of total 
metabolite was compared (Figure 3.2).   The metabolites generated were consistent 
with all forms of vitamin E being metabolized through the same ω-hydroxylation/β-
oxidation pathway we previously characterized for α- and γ-TOH (31).  The 
hepatocytes displayed substrate discrimination based on the structural features 
described.   The degree to which the chromanol ring is methylated appeared to be a 
factor in enzymatic activity toward the vitamers.  Non-methylated and mono-
methylated Tocol and δ-TOH were most effectively converted to the water-soluble 
urinary metabolites, followed by the di-methyl γ-TOH, while the tri-methyl α-TOH 
was poorly metabolized.  The comparison of metabolism of the di-methyl tocopherols  
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Figure 3.2 
Influence of vitamer structural variations on Vitamin E metabolism in HepG2 
hepatocytes.  Confluent cells were incubated 48hours with 25µM substrate and the 
total metabolite in the media was quantified as described in Materials and Methods.   
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revealed a strong inhibitory effect of a methyl group at carbon 5 (β-TOH), while 
methylation at other positions (γ- and ε-TOH) were not as influential.  No significant 
differences in metabolism were noted between the RRR and all-rac isomers of either 
α-TOH or γ-TOH. 
The structural feature contributing greatest to flux through the tocopherol-ω-
oxidation pathway was unsaturation of the phytyl tail.  Each of the three tocotrienols 
were metabolized to a greater extent than their corresponding tocopherols.   
Comparison of uptake of the vitamers by HepG2 cells over time revealed large 
variations in uptake of the various substrates (Figure 3.3).  Similar results were 
obtained when tested in bovine aortal endothelial (BAE) cells which do not metabolize 
vitamin E (data not shown).  These data were consistent with reports of significant 
variation of vitamer uptake in a variety of other cell types (6,37).  As demonstrated in 
Figure 3.3, decreased ring methylation increased the rate of tocopherol incorporation 
into cells.  Tocol displayed the highest rate of cell incorporation.  Tocotrienols were 
more rapidly taken up by cells than their corresponding tocopherols.  There were no 
significant effects of methyl position or phytyl tail racemerization on the rate of cell 
uptake.   
Organelle isolation assays revealed rapid distribution of vitamin E from the 
extracellular media into mitochondria, here used as an indicator of rate of vitamer 
movement to inner cellular membranes where the P450 ω-hydroxylation of the 
vitamers likely occurs.  After 2 hours of incubation  with 25µM substrate, the 
tocotrienols were present in the mitochondrial fraction at levels more than 3 fold 
higher than that of the corresponding tocopherols (data not shown). 
Microsomal Metabolism of Tocochromanols 
The culture data strongly suggested structural discrimination by the enzyme(s) 
involved in the ω-oxidation/β-oxidation of the tocochromanol substrates.  The level of  
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Figure 3.3 
Variations in HepG2 cell uptake of vitamin E over 48hours.  Confluent cells were 
incubated with 25µM vitamer and harvested at 6, 18, 30, and 48 hours and the amount 
of vitamer associated with the cell was measured.  The area under the curve (A.U.C) 
was determined using Origin 7.0 software. 
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metabolism is heavily influenced by not only the enzymatic activity, but also the 
actual substrate concentrations presented to the enzyme. As such, the variation in 
cellular uptake and distribution of the vitamers over time obscured the degree to which 
the actual enzymatic activity was controlling metabolic discrimination.  We have 
developed a microsomal assay in which the substrates are presented to the P450 
enzyme through incorporation of the vitamin directly into the microsomal membrane.  
Assays were conducted for each of the substrates using microsomes isolated from 
human liver or from insect cells selectively expressing recombinant human liver 
CYP4F2.  
First, a comparison of the rate of incorporation of the various tocochromanols 
into human liver microsomal membranes was undertaken.  The results in Figure 3.4 
show not only wide differences in the rates of incorporation, but a large range in 
membrane substrate capacity.  As seen in HepG2 cells, both the rate of incorporation 
and the overall capacity of the membrane for the tocotrienols exceeds that of the 
tocopherols.  Loading was linear with added substrate throughout the concentration 
range used for this and all subsequent experiments (data not shown). 
The variation in membrane loading efficiency (incorporated substrate per 
added substrate) between the vitamers results in two pools of substrate during the 
tocopherol-ω-hydroxylase reaction: the membrane associated pool, and the pool of 
substrate remaining in the aqueous phase (complexed with BSA).  Pre-incubation of 
substrate with the microsomes consistently yielded higher levels of metabolite 
production, suggesting that the membrane-associated substrate is the pool upon which 
tocopherol-ω-hydroxylase acts (data not shown).   
Tocopherol-ω-hydroxylase activity of human liver microsomes was compared 
under two conditions.  In both, microsomes were pre-incubated with concentrations of 
substrate that had been previously determined to yield 100 nmol/mg protein in the  
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Figure 3.4 
Incorporation of Vitamin E into microsomal membranes over time.  100µg/ml human 
liver microsomes were incubated with 25µM vitamer-BSA complex over a 70 min 
time period.  The membrane associated vitamer was separated from the remaining 
aqueous vitamer by 100,000 x g centrifugation and the amount of vitamer associated 
with the membrane was measured.  The area under the curve (A.U.C) was determined 
using Origin 7.0 software. 
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membrane (10 µM in the total reaction volume) at the end of the pre-incubation 
period.  As a result the remaining unbound substrate concentrations varied greatly 
depending on the substrate used (Figure 3.5A, inset).  In the first condition, the 
microsomal reaction was carried out in the presence of both membrane-associated and 
unbound substrate.  In the second condition, microsomes were re-isolated by 
ultracentrifugation and the reaction carried out in the presence of membrane-
associated substrate only.  The results showed a similar pattern of vitamer metabolism 
under both conditions (Figure 3.5A).  This occurred despite the wide range of total 
vitamer concentration present due to unbound substrate in the first condition (Figure 
3.5A, inset).  The overall activity under the first condition was higher, probably 
because of the continued uptake of aqueous vitamer into the membrane during the 
reaction, or from a partial loss of activity during membrane re-isolation under the 
second condition.   
A time course of metabolite production in human liver microsomes was 
conducted.  When the linear production of metabolite was extrapolated to the earliest 
time points of the reaction, it indicated a rapid initial burst of metabolite production, 
followed by a slower linear increase in metabolite (Figure 3.5B).  This phenomenon 
occurs often in reactions in which the enzyme and substrate are components of the 
same microsomal membrane. The substrate in close proximity to the enzyme is rapidly 
catabolized before additional substrate can move into, or through the membrane to 
access the enzyme (38).  This then results in a slow phase of metabolism, whose rate is 
limited by the rate of substrate access to the enzyme.  Taken together, the results of 
Figure 3.5 show the tocopherol-ω-hydroxylase acts on the membrane vitamer pool.  
Additionally, the rate of catabolism may be influenced by both incorporation of 
tocopherol into the membrane, and the rate at which the vitamers move through the 
membrane to access the enzyme.      
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Figure 3.5 
(A) Comparison of 13’OH + 13’COOH metabolite formation of Vitamin E vitamers 
loaded to equimolar concentrations in the membrane of human liver microsomes.   
100ug/ml human liver microsome was pre-incubated 60min with the various 
concentrations of vitamer-BSA complex pre-determined to reach 100 nmol VitE/mg 
protein in the membrane.   A 20 min reaction was carried out with or without the 
removal of the remaining aqueous vitamin E, which was removed by 100,000 x g 
centrifugation (See Material and Methods).  The reaction was initiated by the addition 
of 0.5mM NADPH + NAD.   Inset shows the total amount of vitamin E remaining in 
the reaction with or without the removal of the aqueous vitamin pool.  (B) Time 
course of 13’OH + 13’COOH metabolite formation in human liver microsomes pre-
incubated 60 min with 25µM vitamer.  Reaction initiated by the addition of 1mM 
NADPH + NAD.  Amount of initial formation of metabolite indicated by the y-
intercept of the extrapolated dotted line. 
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Kinetics of vitamer metabolism 
Kinetic analyses of microsomal tocochromanol metabolism were carried out 
with each individual substrate.  While the majority of tocopherols tested displayed 
typical Michaelis-Menten kinetics, the tocotrienols, and to a lesser extent δ-TOH and 
tocol demonstrated concentration-dependent inhibition of their own metabolism at 
high substrate concentrations as illustrated in Figure 3.6A for γ-T3.  Kinetic analyses 
of data from both human liver and CYP4F2 microsomes were carried out over a range 
of concentrations for the vitamers below those resulting in the inhibition (Figure 3.6).  
α-TOH and rac-α-TOH displayed simple hyperbolic kinetics, while the other vitamers 
displayed sigmoidal kinetics typical of allosteric enzyme reactions.  As such, kinetic 
constants were determined using Origin software to fit the data to both Michaelis-
Menten (hyperbolic) and Hill (sigmoidal) curves as shown below: 
 
Michaelis-Menten:    V = Vmax[S]/(km + [S]) 
 
Hill:    V = Vmax[S]
n/(k
 n +[S]
 n) 
 
The Hill equation differs from the Michaelis-Menten equation only in the 
variable “n”, the Hill coefficient, which is a measure of the positive (n>1) or negative 
(n<1) cooperativity of the enzyme with its substrate.  A value of n = 1 indicates no 
cooperativity.  Tocopherol-ω-hydroxylase substrates could be categorized into three 
groups: those fitting only Michaelis-Menten kinetics (α- and rac-α-TOH), those fitting 
both Michaelis-Menten or Hill kinetics (γ-, rac-γ-, β-, ε-, δ-TOH, and tocol), and those 
fitting Hill kinetics only (all three tocotrienols).  The results indicate positive 
cooperativity for all three tocotrienols, and either some or no cooperativity for the 
tocopherols (Table 3.1).  Determination of Vmax and Km demonstrated a remarkably  
 
 
98 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 
Kinetic analysis of vitamin E metabolism in Human Liver Microsome (HLM) & 
CYP4F2 microsome.  (A) 100ug/ml human liver microsome or (B) 20pmol/ml 
CYP4F2 microsome was pre-incubated with vitamer-BSA complex for 60 min.  10 or 
20 min reaction was initiated by the addition of 1mM NADPH + NAD.   
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Table 3.1 
Kinetic parameters for human liver microsome (HLM) or CYP4F2 microsome. 
Kinetic fit to Michaelis-Menten or Hill equation was done using Origin 7.0 curve-
fitting software.    
 
HLM  Vmax (E-03) 
Metab/Chol/10min  Error  
Km 
(µM) 
Error   n  Error   R
2 
α-TOH  10.72  +/-1.45     306.2  +/-69.8     1.00  +/-0.00     0.977 
rac-α  9.22  +/-1.42     318.3  +/-74.1     1.00  +/-0.00     0.982 
γ-TOH  152.51 
+/-
20.72     145.6  +/-42.4     1.05  +/-0.12     0.994 
rac-γ  105.41 
+/-
14.50     217.7  +/-54.9     1.07  +/-0.08     0.998 
β-TOH  14.39  +/-2.31     134.2  +/-44.6     1.00  +/-0.11     0.994 
ε-TOH  37.72  +/-3.55     155.5  +/-23.8     1.25  +/-0.07     0.998 
δ-TOH  53.69  +/-5.43     56.1  +/-8.0     1.61  +/-0.15     0.995 
Tocol  92.27 
+/-
43.07     61.8  +/-45.1     1.13  +/-0.19     0.992 
α-T3  73.81  +/-8.14     66.8  +/-8.6     1.60  +/-0.08     0.999 
γ-T3  210.29 
+/-
70.21     47.3  +/-25.1     1.12  +/-0.14     0.996 
δ-T3  133.24 
+/-
46.06     34.5  +/-16.3     1.44  +/-0.27     0.986 
                  
CYP4F2  Vmax (E-02) 
Metab/Chol/20min  Error  
Km 
(µM) 
Error   n  Error   R
2 
α-TOH  4.82  +/-0.95   36.7  +/-12.5   1.00 +/-0.00   0.965 
rac-α  4.59  +/-0.63   29.6  +/-8.1   1.00 +/-0.00   0.963 
γ-TOH  62.56  +/-9.93   38.0  +/-10.2   1.25 +/-0.15   0.994 
rac-γ  60.31 
+/-
23.63   50.6  +/-33.2   1.18 +/-0.28   0.981 
β-TOH  11.29  +/-4.22    19.8  +/-15.7    1.01  +/-0.53    0.912 
ε-TOH  46.38 
+/-
18.63    42.9  +/-32.4    1.08  +/-0.31    0.973 
δ-TOH  26.31  +/-4.07    14.6  +/-3.2    1.60  +/-0.22    0.991 
Tocol  52.34 
+/-
21.95    16.3  +/-13.0    1.09  +/-0.35    0.966 
α-T3  91.59 
+/-
18.11    8.0  +/-2.2    1.69  +/-0.34    0.979 
γ-T3  102.80 
+/-
46.48    9.7  +/-5.5    1.36  +/-0.20    0.993 
δ-T3  93.28 
+/-
21.49    6.6  +/-1.7    2.00  +/-0.41    0.979 
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large variation in enzyme activity for the vitamers based on the aforementioned   
structural features, disentangled from the confounding effects of cell or membrane 
substrate incorporation.  The pattern of substrate structural effects on enzyme activity 
was similar between human liver microsomes and CYP4F2 microsomes.  Apparent 
Km, a measure of affinity of enzyme for substrate, increased with number of methyl 
groups around the chromanol ring, with α-TOH showing the least affinity for the 
enzyme compared with the unmethylated tocol and monomethylated δ-TOH which 
exhibited the highest enzyme affinities.  There were no significant effects of methyl 
position (γ- vs. β- vs. ε-TOH) or phytyl tail stereochemistry (RRR- vs. Rac-α- or γ-
TOH) on enzyme affinity.  Unsaturation of the phytyl tail proved to exert the strongest 
effect on enzyme affinity, with all three tocotrienols displaying low Km values 
compared with their tocopherol counterparts.   
Vmax, a measure of maximal specific activity of the enzyme toward a 
substrate, did not show a pattern based on number of methyls substituted around the 
chromanol ring, as the dimethyl γ-TOH shows the highest activity.  The position of the 
methyl group appears to play a greater role, with the 5-position methyl group most 
greatly attenuating the activity as evidenced by the low activities of the α- and β-
TOH.  The presence of the 7-position methyl seems to have the greatest positive effect 
on activity, given the activities of γ- and ε-TOH.  That the enzyme does not possess as 
high activity toward ε-TOH as toward γ-TOH may again be due to the presence of the 
addition inhibitory 5-position methyl on the ε-TOH molecule.  Stereochemistry of the 
phytyl tail does not influence the specific activity of the enzyme toward vitamin E 
(RRR- vs. Rac).  The tocotrienols display a very high Vmax value compared with their 
analogous tocopherols.  Taken together with the low Km values of the tocotrienols, the 
tocopherol-ω-hydroxylase appears to display the greatest overall preference for the 
unsaturated vitamin E molecule above other structural features.    
 
 
101 
α-Tocopherol-Mediated Stimulation of Vitamer Metabolism 
  The effect of the vitamers on the metabolism of each other was investigated in 
Rat liver microsomes.  γ-TOH was incubated with several concentrations of α-, rac-α-
, β-, or δ-TOH and γ-T3 (Figure 3.7).  γ-T3, which is highly metabolized, acted as a 
good inhibitor of γ-TOH even at low concentrations.  δ-TOH, which is metabolized at 
rates more comparable to γ-TOH, was a moderate inhibitor of γ-metabolism.  Based on 
these results, α-, rac-α, and β-TOH were all expected to show little inhibition, given 
the fact that they are poorly metabolized.  Surprisingly, no inhibition was observed.  
Instead, these tocopherols were found to increase the metabolism of γ-TOH, with the 
effects greatest for the α- vitamers irregardless of stereochemistry of their phytyl tail.  
Subsequent experiments revealed this stimulative effect of α-TOH toward all 
tocopherols and tocotrienols tested (data not shown).  This stimulatory effect was 
observed in both human liver and CYP4F2 microsomes.  α-TOH did not affect the 
membrane uptake of the other vitamers tested.  At high concentrations of α-TOH, i.e. 
500 µM, the stimulation disappeared and α-TOH became inhibitory.  To test whether 
α-TOH was stimulating its own metabolism, RRR-d6α-TOH was used as a substrate 
to distinguish it from the unlabeled α-TOH.  Unlike its effects on the non-α vitamers, 
α-tocopherol is unable to stimulate its own metabolism (data not shown).    
We suspected α-TOH was influencing the allosteric interaction between 
tocopherol-ω-hydroxylase and its substrates.  Kinetic analyses of γ-TOH or d6α-TOH 
metabolism were carried out in the presence or absence of 50 µM α-TOH (Figure 
3.8).  In the absence of α-TOH, γ-TOH displayed the expected sigmoidal kinetics and 
non-linear Lineweaver-Burk kinetics typical of homotropic cooperativity.  In the 
presence of α-TOH, the kinetics become hyperbolic and the Lineweaver-Burk analysis 
reverted to linearity (not shown).  Additionally, the Vmax of the reaction increased in 
the presence of α-TOH while the Km was unaffected.  In the presence of unlabeled α- 
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Figure 3.7   
Influence of various vitamers on metabolism of 10µM  γ-TOH in Rat liver 
microsomes.  100µg/ml rat liver microsome was pre-incubated with 10µM γ-TOH-
BSA complex with or without the addition of several concentrations of various 
competing vitamers.  A 20min reaction was then initiated by the addition of 0.5 mM 
NADPH + NAD and the combined levels of the 13’OH- and 13’COOH- γ-TOH 
metabolites generated was measured per microsomal cholesterol.  Data is expressed as 
a percent of the γ-TOH-only (control) reaction. 
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Figure 3.8 
Kinetics of α-TOH stimulation of γ-TOH or d6α-TOH metabolism on Rat Liver 
Microsomes.  100µg/ml microsomal protein was preincubated with substrate + 50µM 
α-TOH for 60 min, followed by a 20 min reaction initiated by the addition of 0.5mM 
NADPH + NAD.  Kinetic parameters are given (+/-error) based on best fit to the Hill 
equation. 
0 50 100 150 200 250 300 350
0.0
0.1
0.2
0.3
0.4
0.5
0.6
 γ-                                 0.471 (0.106)  205.1 (77.3)  1.34 (0.23)
 γ- (+50µM α-TOH)      0.722 (0.086)  258.0 (57.1)  1.10 (0.08)
 d6α-                            0.101 (0.002)   70.3 (3.0)     1.38 (0.05)
 d6α- (+50µM α-TOH) 0.109 (0.003)   93.4 (5.2)     0.98 (0.03)
E
n
z
y
m
e
 
A
c
t
i
v
i
t
y
µ
m
o
l
e
/
µ
m
o
l
e
 
C
h
o
l
e
s
t
e
r
o
l
γ- or d6α-TOH (µM) 
Vmax (error)  Kmapp (error)  n (error)
  
 
 
104 
TOH, metabolism of d6α-TOH showed no increase in Vmax, while the increase in 
Km was not significant. 
 
Discussion 
  Despite the high intake of vitamers such as γ-TOH the body is very efficient in 
retaining mainly α-TOH while eliminating the non α-forms.  The mechanisms 
underlying this apparent paradox in vitamin E bioavailability are just recently 
becoming clear.  Several mechanisms have been proposed to explain the preferential 
retention of α-TOH, including loss of other forms in the bile, conversion of γ-TOH to 
α-TOH by microflora in the gut, and the preferential secretion of α-TOH into the 
plasma by the hepatic α-TTP (19,20,39).  We have previously described the first 
enzyme shown to be involved in regulation of vitamin E status and demonstrated its 
preferential metabolism of γ-TOH over α-TOH (31).  This enzyme, cytochrome P450 
CYP4F2, is expressed in liver, kidney, and intestinal cells, and is constitutively 
expressed in several cell lines including the hepatoblastoma HepG2 and the lung 
adenocarcinoma A549 (40,41).  Here, we further characterize this enzyme and 
demonstrate the importance of key structural features of its many tocochromanol 
substrates.   
  In HepG2 cell culture, human liver microsomes, and CYP4F2 microsomes, the 
two structural features most determining tocopherol-ω-hydroxylase activity toward 
each substrate were (a) the presence of the three double bonds along the phytyl tail and 
(b) the position of the methyl groups around the chromanol ring.  The degree to which 
the α-T3 vitamer was metabolized compared with α-TOH indicates the dominance of 
phytyl tail unsaturation over the inhibitory effect of the methyl group at the 5 carbon 
position of the chromanol ring.  While the number of methyl groups initially appeared 
to play a role in the differences in activity, these differences most likely indirectly  
 
 
105 
reflected the effects of methyl position and rates of vitamer incorporation into the cells 
or microsomal membranes.  Racemerization around the chiral carbons of the tail did 
not significantly affect the rate of metabolism of α-TOH indicating the enzyme has no 
preference between the natural and synthetic forms of the vitamin.  The differences in 
the metabolism of RRR-γ-TOH and all-rac γ-TOH suggest the stereochemistry of the 
phytyl tail may only affect metabolism when the enzyme activity toward the substrate 
is high.   
The membrane environment appears to play a major role in the apparent 
activity of tocopherol-ω-hydroxylase toward its substrates.  The evidence presented 
here indicates the membrane is the true environment of the entire reaction, with 
Vitamin E-P450 interaction occurring within the confines of the membrane.  In whole 
cells, the substrates are not only incorporated into the whole cells at varying rates, but 
the access to the inner organelle membranes also varies greatly among the substrates, 
resulting in different substrate concentrations at the putative intracellular site of 
enzyme activity.  Similarly, microsomal data reveal the strong influence of substrate 
access to the membrane-associated enzyme.  As such, the kinetics of metabolism are 
not equivalent to those of an aqueous system (38).  Differences in rates of membrane 
association of the vitamer as well as differences in rates of lateral motion through the 
membrane may influence the apparent affinity of the enzyme for vitamers possessing 
different structural features.  The apparent Km may then better be a measure of 
affinity of substrate for the combined enzyme-membrane system.  Vmax, which is not 
influenced by substrate access to the enzyme, may be a better indicator of substrate 
specificity of the actual enzyme.   
  The allosteric nature of the tocopherol-ω-hydroxylase was an unexpected 
finding, as no indication of allostery has been associated for this enzyme with its 
previously characterized substrates, LTB4 or arachidonic acid (34,36,42).  The best  
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studied case of cooperativity in a cytochrome P450 system is that of CYP3A4, which 
displays both homotropic and heterotropic cooperativity (43,44).  CYP3A4 possesses 
a large active site, able to bind both small molecules such as naphthalene and large 
substrates such as dibenzopyrenes.  Such a large active site may accommodate the 
simultaneous binding of two molecules.  Shou et al (44) described the simultaneous 
binding of two substrates to CYP3A4 with no effect on Km, and surmised that the 
binding of both substrates (or substrate + effector) occur within the same active site, 
and later (45) that this active site possesses two distinct substrate-binding sites.  The 
results of Harlow and Halbert (46) supported this theory.  Reduction in the size of the 
proposed effector site of the CYP3A4 enzyme by site-directed mutagenesis mimicked 
the stimulation produced by α-naphthoflavone, a known effector of CYP3A4.  Based 
on this model, positive cooperativity can occur during enzyme-substrate interactions 
by increasing Vmax, decreasing Km, or both.  The binding of the effector molecule 
may alter the size and shape of the active site to allow for increased affinity of enzyme 
for substrate, thus lowering the Km.  Kcat of substrate + effector may also be higher 
than Kcat of substrate alone, thereby increasing Vmax (46).  The second scenario is 
consistent with our findings for tocopherol-ω-hydroxylase in the presence of α-TOH, 
where the substrate activity of the enzyme increased toward the non-α vitamers with 
no significant change in Vmax (Figure 3.8).  This may reflect several scenarios 
including (a) one large active site containing two substrates, (b) a large “active site” 
containing two binding sites, or (c) two geographically separated binding sites.  These 
possibilities merit further study.   
  There is a large body of evidence showing supplementation of α-TOH 
decreases plasma levels of γ-TOH (24,25).  Additionally, supplementation of rats with 
equivalent amounts of α- and γ-TOH causes a greater increase in urinary γ-CEHC 
excretion than when γ-TOH is fed alone (47).  Our finding here of the stimulatory  
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effect of α-TOH on the enzymatic metabolism of non-α-TOH vitamers presents a 
mechanism by which these phenomena may occur.  The development of this 
heterotropic cooperativity may be an enzymatic means by which the body can 
decrease the elimination of non-α-TOH vitamers under conditions where tissue α-
TOH is limited, while at the same time enhancing their elimination when α-TOH 
status is sufficient.  This effector activity is observed for the synthetic racemic-α-TOH 
as well, highlighting the role of tocopherol-ω-hydroxylase in the influence of vitamin 
E supplementation on plasma and tissue tocochromanol status.   
We previously reported that other members of the CYP4F family, 4F3A and 
4F3B, show very little activity toward tocopherols despite having a high degree of 
sequence homology with CYP4F2.  The possibility that other P450 enzymes exist in 
the liver which are able to metabolize vitamin E seems unlikely based on the evidence 
presented here.  The kinetics of metabolism in human liver microsomes showed 
similar profiles to that of CYP4F2 microsomes for the vitamers, with no evidence of 
the biphasic kinetics normally associated with two enzymes acting on the same 
substrates.  Any additional hepatic enzyme possessing significant tocopherol-ω-
hydroxylase activity would need to also possess similar kinetics and substrate 
specificity as that of CYP4F2.  Additionally, the comparative flux of the vitamers 
through the rest of the pathway (β-oxidation) has not been determined.  However, 
when differences in cell vitamer uptake are taken into account, the pattern of the 
complete ω/β-oxidation in the hepatocyte system and of ω-hydroxylation in the single 
enzyme system show overall similarities, indicating the tocopherol-ω-hydroxylase 
mediated hydroxylation may be the major discriminatory step within the pathway. 
  The effects of substrate structure on tocopherol-ω-hydroxylase activity are 
very interesting in light of the relative affinities of the various tocochromanols for the 
hepatic α-tocopherol transfer protein as determined by Hosomi et al (20).  RRR-α- 
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TOH exhibited the highest affinity for the protein (assigned 100%), followed by β-
TOH (38%), α-T3 (12%), SRR-α-TOH (11%), γ-TOH (9%), and δ-TOH (2%).   
Unfortunately, the affinities of the more highly metabolized γ- and δ-tocotrienols were 
not determined.  These affinities are for the most part the inverse to their ability to act 
as ω-hydroxylase substrates, suggesting a collaborative role for these two proteins in 
producing and maintaining the α-TOH enriched phenotype.  The fact that TTP shows 
a high degree of specificity for the RRR stereochemistry of the phytyl tail, while the 
tocopherol-ω-hydroxylase does not, suggests that α-TTP may be the main regulatory 
feature of the preference of natural vitamin E over synthetic.  However, data from TTP 
knockout mice shows the plasma of these mice lacking the transfer protein is still 
enriched in α-TOH over γ-TOH, although total tocopherol levels are greatly reduced 
relative to controls (48).  Additionally, rats fed an inhibitor of the tocopherol-ω-
hydroxylase, sesamin, have plasma γ-TOH levels nearing those of α-TOH (4).  Taken 
together, these data support the following model.  Dietary tocochromanols are taken 
into the liver without pre-hepatic discrimination (49).  In the absence of α-TTP, there 
is no preference for α-TOH being removed from the liver.  All the vitamers may leave 
the liver at equal rates.  However, due to the specificity of the tocopherol-ω-
hydroxylase, less α-TOH is metabolized and more will subsequently be available to 
leave the liver even by non-selective export, albeit in lower amounts than in the 
presence of TTP.  In the absence (i.e. inhibition) of tocopherol-ω-hydroxylase, other 
non-α-TOH vitamers are not catabolized.  The lower rate of transfer of non-α-TOH 
out of the liver by a α-TTP mediated mechanism not as influential in regulating 
vitamin E status, since the non-α-TOH is present long enough to be exported out of 
the liver.   
The reasons behind the structural selectivity that both α-TTP and the 
tocopherol-ω-hydroxylase exhibit are not clear.  This function may be desirable to rid  
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the system of potentially toxic or less active vitamers (1,15,17), or to generate 
bioactive metabolites of these vitamers (13,27).  On the other hand the numerous 
potential benefits of the non-α forms of vitamin E may be lost upon their rapid 
catabolism and elimination.  The fact that many organisms throughout nature exhibit 
selective retention of α-TOH above the other vitamers may indicate a selective 
advantage to this trait.  
The activities of the tocopherol transfer protein and the tocopherol-ω-
hydroxylase enzyme are only in recent years being clarified.  As we continue to learn 
more about the roles of specific proteins in the regulation of tocopherol status, we find 
an increasingly complex means by which the body appears to select among vitamers 
differing in minor structural features for retention or elimination.  Elucidation of these 
mechanisms opens new doors for enhancing the plasma levels of vitamers (e.g. γ-
TOH) which would otherwise be eliminated.  Given the potential therapeutic effects of 
forms of vitamin E other than α-TOH, new strategies may emerge to impact the ability 
of these tocochromanols to be used in the prevention or treatment of a variety of 
conditions. 
  
 
 
110 
References 
 
1.  Bieri, J. G., and McKenna, M. C. (1981) Am. J. Clin. Nutr. 34, 289-295 
2.  Kamal-Eldin, A., and Appelqvist, L. A. (1996) Lipids 31, 671-701 
3.  Burton, G. W., and Ingold, K. U. (1986) Acc Chem Res 19, 194-201 
4.  Yamashita, K., Nohara, Y., Katayama, K., and Namiki, M. (1992) J Nutr 122, 
2440-2446 
5.  Serbinova, E., Kagan, V., Han, D., and Packer, L. (1991) Free Radic Biol Med 
10, 263-275 
6.  Saito, Y., Yoshida, Y., Akazawa, T., Takahashi, K., and Niki, E. (2003) J Biol 
Chem 278, 39428-39434 
7.  Boscoboinik, D., Szewczyk, A., Hensey, C., and Azzi, A. (1991) J Biol Chem 
266, 6188-6194 
8.  Tasinato, A., Boscoboinik, D., Bartoli, G. M., Maroni, P., and Azzi, A. (1995) 
Proc Natl Acad Sci U S A 92, 12190-12194 
9.  Ricciarelli, R., Zingg, J. M., and Azzi, A. (2000) Circulation 102, 82-87 
10.  Keaney, J. F., Jr., Simon, D. I., and Freedman, J. E. (1999) Faseb J 13, 965-
975 
11.  Hoglen, N. C., Waller, S. C., Sipes, I. G., and Liebler, D. C. (1997) Chem Res 
Toxicol 10, 401-407 
12.  Williamson, K. S., Gabbita, S. P., Mou, S., West, M., Pye, Q. N., Markesbery, 
W. R., Cooney, R. V., Grammas, P., Reimann-Philipp, U., Floyd, R. A., and 
Hensley, K. (2002) Nitric Oxide 6, 221-227 
13.  Jiang, Q., Elson-Schwab, I., Courtemanche, C., and Ames, B. N. (2000) Proc 
Natl Acad Sci U S A 97, 11494-11499  
 
 
111 
14.  Kushi, L. H., Folsom, A. R., Prineas, R. J., Mink, P. J., Wu, Y., and Bostick, 
R. M. (1996) N Engl J Med 334, 1156-1162 
15.  Yu, W., Simmons-Menchaca, M., Gapor, A., Sanders, B. G., and Kline, K. 
(1999) Nutr Cancer 33, 26-32 
16.  Qureshi, A. A., Mo, H., Packer, L., and Peterson, D. M. (2000) J Agric Food 
Chem 48, 3130-3140 
17.  McIntyre, B. S., Briski, K. P., Tirmenstein, M. A., Fariss, M. W., Gapor, A., 
and Sylvester, P. W. (2000) Lipids 35, 171-180 
18.  Parker, R. A., Pearce, B. C., Clark, R. W., Gordon, D. A., and Wright, J. J. 
(1993) J Biol Chem 268, 11230-11238 
19.  Traber, M. G., and Kayden, H. J. (1989) Am J Clin Nutr 49, 517-526 
20.  Hosomi, A., Arita, M., Sato, Y., Kiyose, C., Ueda, T., Igarashi, O., Arai, H., 
and Inoue, K. (1997) FEBS Lett 409, 105-108 
21.  Arita, M., Nomura, K., Arai, H., and Inoue, K. (1997) Proc Natl Acad Sci U S 
A 94, 12437-12441 
22.  Morinobu, T., Yoshikawa, S., Hamamura, K., and Tamai, H. (2003) Eur J Clin 
Nutr 57, 410-414 
23.  Kaneko, K., Kiyose, C., Ueda, T., Ichikawa, H., and Igarashi, O. (2000) J Lipid 
Res 41, 357-367 
24.  Handelman, G. J., Machlin, L. J., Fitch, K., Weiter, J. J., and Dratz, E. A. 
(1985) J Nutr 115, 807-813 
25.  Burton, G. W., Traber, M. G., Acuff, R. V., Walters, D. N., Kayden, H., 
Hughes, L., and Ingold, K. U. (1998) Am J Clin Nutr 67, 669-684 
26.  Schonfeld, A., Schultz, M., Petrizka, M., and Gassmann, B. (1993) Nahrung 
37, 498-500  
 
 
112 
27.  Wechter, W. J., Kantoci, D., Murray, E. D., Jr., D'Amico, D. C., Jung, M. E., 
and Wang, W. H. (1996) Proc Natl Acad Sci U S A 93, 6002-6007 
28.  Chiku, S., Hamamura, K., and Nakamura, T. (1984) J Lipid Res 25, 40-48 
29.  Hattori, A., Fukushima, T., Yoshimura, H., Abe, K., and Imai, K. (2000) Biol 
Pharm Bull 23, 1395-1397 
30.  Lodge, J. K., Ridlington, J., Leonard, S., Vaule, H., and Traber, M. G. (2001) 
Lipids 36, 43-48 
31.  Sontag, T. J., and Parker, R. S. (2002) J Biol Chem 277, 25290-25296 
32.  Birringer, M., Drogan, D., and Brigelius-Flohe, R. (2001) Free Radic Biol Med 
31, 226-232 
33.  Kikuta, Y., Kusunose, E., Kondo, T., Yamamoto, S., Kinoshita, H., and 
Kusunose, M. (1994) FEBS Lett 348, 70-74 
34.  Powell, P. K., Wolf, I., Jin, R., and Lasker, J. M. (1998) J Pharmacol Exp Ther 
285, 1327-1336 
35.  Christmas, P., Ursino, S. R., Fox, J. W., and Soberman, R. J. (1999) J Biol 
Chem 274, 21191-21199 
36.  Kikuta, Y., Kusunose, E., and Kusunose, M. (2000) J Biochem (Tokyo) 127, 
1047-1052 
37.  Sen, C. K., Khanna, S., Roy, S., and Packer, L. (2000) J Biol Chem 275, 
13049-13055 
38.  Takakuwa, Y., Nishino, H., Ishibe, Y., and Ishibashi, T. (1994) J Biol Chem 
269, 27889-27893 
39.  Elmadfa, I., Kim, S. W., Reutlinger, M., and Siewert, R. (1989) Z 
Ernahrungswiss 28, 36-48 
40.  Kikuta, Y., Miyauchi, Y., Kusunose, E., and Kusunose, M. (1999) DNA Cell 
Biol 18, 723-730  
 
 
113 
41.  Yamane, M., and Abe, A. (2000) J Biochem (Tokyo) 128, 827-835 
42.  Jin, R., Koop, D. R., Raucy, J. L., and Lasker, J. M. (1998) Arch Biochem 
Biophys 359, 89-98 
43.  Houston, J. B., and Kenworthy, K. E. (2000) Drug Metab Dispos 28, 246-254 
44.  Shou, M., Grogan, J., Mancewicz, J. A., Krausz, K. W., Gonzalez, F. J., 
Gelboin, H. V., and Korzekwa, K. R. (1994) Biochemistry 33, 6450-6455 
45.  Shou, M., Mei, Q., Ettore, M. W., Jr., Dai, R., Baillie, T. A., and Rushmore, T. 
H. (1999) Biochem J 340 ( Pt 3), 845-853 
46.  Harlow, G. R., and Halpert, J. R. (1998) Proc Natl Acad Sci U S A 95, 6636-
6641 
47.  Kiyose, C., Saito, H., Kaneko, K., Hamamura, K., Tomioka, M., Ueda, T., and 
Igarashi, O. (2001) Lipids 36, 467-472 
48.  Terasawa, Y., Ladha, Z., Leonard, S. W., Morrow, J. D., Newland, D., Sanan, 
D., Packer, L., Traber, M. G., and Farese, R. V., Jr. (2000) Proc Natl Acad Sci 
U S A 97, 13830-13834 
49.  Traber, M. G., Burton, G. W., Ingold, K. U., and Kayden, H. J. (1990) J Lipid 
Res 31, 675-685 
 
  
 
  114 
 
 
 
 
 
 
 
 
 
CHAPTER IV 
 
TOCOTRIENOLS BUT NOT TOCOPHEROLS REDUCE 
THE MOBILITY OF LIPID MEMBRANE COMPONENTS 
AND INHIBIT MICROSOMAL CYTOCHROME P450 
ACTIVITY 
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Abstract 
The tocopherol and tocotrienol vitamers of the vitamin E family of 
tocochromanols have recently been demonstrated by our lab to be degraded to water 
soluble metabolites through the action of the microsomal cytochrome P450 (CYP4F2) 
tocopherol-ω-hydroxylase enzyme and subsequent β-oxidation of the phytyl side 
chain.  Tocotrienols differ from tocopherols only in the presence of three double bonds 
along the phytyl tail.  Kinetic analysis of activity of tocopherol-ω-hydroxylase toward 
these substrates reveals a substantial concentration-dependent impairment of enzyme 
activity by tocotrienols incorporated into the microsomal membrane, an effect not 
shared by the tocopherols.  We tested the effect of tocopherols and tocotrienols on 
other microsomal cytochrome P450 enzymes to test if this was a generalized effect on 
P450 enzymes.  The metabolism of testosterone (CYP3A, 2C), 7-ethoxycoumarin 
(CYP1A, 2B, 2E), lauric acid (CYP4A), and p-nitrophenol (CYP2E) were inhibited to 
varying degrees by tocotrienols, but not tocopherols.  This inhibition was non-
competitive.  Similar effects on enzyme activity were seen by enriching microsomal 
membranes with cholesterol or unsaturated fatty acids in the membrane, but not with 
saturated fatty acids.  Analysis of membrane physical characteristics by diphenyl-
hexatriene fluorescence anisotropy and pyrene eximerization revealed that γ-
tocotrienol decreased the rotational mobility of membrane lipids more than α-
tocopherol, while both tocopherols and tocotrienols decreased the lateral diffusivity 
within the membrane.  This decrease in membrane fluidity is similar to cholesterol 
which also decreases the activity of the electron transport partners involved in 
reduction of P450 enzymes.  In the absence of microsomal cytochrome b5, γ-
tocotrienol was not as inhibitory toward P450 activity as when b5 was present.  We 
suggest the incorporation of tocotrienols into microsomal membranes disturbs the 
interactions between cytochrome b5 and cytochrome P450, resulting in inhibition of  
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those P450 enzymes whose activity is strongly modified by cytochrome b5 activity.  
This effect may play a role in the reported apoptotic effects of tocotrienols in various 
cell lines and highlights the importance of the tocopherol-ω-hydroxylase pathway in 
minimizing membrane tocotrienol concentration. 
 
Introduction 
Vitamin E exists in nature as two classes of tocols, the tocopherols (TOH) and 
the tocotrienols (T3).  The tocotrienols differ from the tocopherols only in the 
presence of three double bonds along the phytyl tail of the vitamin molecule at 
positions 3’, 7’, and 11’.   α-Tocopherol is the major form of vitamin E found in 
plasma and tissues despite the high intake of other forms of the vitamin (1).  Normal 
plasma levels of α-tocopherol range from 15-35 µM, while the tocotrienols are 
normally found in only trace amounts (2).  Even when supplemented at 250 mg/day, 
plasma levels of α-T3 reached only about 1 µM (3).   
The structural differences between the tocopherols and tocotrienols result in 
large differences in bioactivities.  α-TOH is the most bioactive form of the vitamin as 
determined by the rat fetal resorption assay, while α-T3 possessed only 0.3% of the 
activity of α-TOH (4).  The bioactivities of γ- and δ-T3 were below detection.  These 
differences in activity may be largely explained by the very low levels of tocotrienols 
achieved in tissues relative to α-TOH.   
While the tocopherols and tocotrienols both possess vitamin E activity in this 
animal model, the mechanism behind this activity has not been elucidated.  The 
classically accepted function of these molecules has been as antioxidants, in which 
both forms of vitamin E are able to scavenge the chain-propagating peroxyl radical 
(5).  Since these molecules are lipophilic, this antioxidant function occurs in the lipid 
environment of membranes.   As such, the mobility and location of these molecules  
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within the membrane will affect their interaction in with radicals, factors which are 
partially dependent on the structure of the phytyl tail (6).  α-T3 and α-TOH were 
reported to possess equivalent peroxyl radical scavenging capabilities in hexane 
solution, but the protection by α-T3 against lipid peroxidation was greater than by α-
TOH in liposomes (1.5-fold) and in rat liver microsomes (40-fold) (7).  In the same 
study, when P450 oxidative damage was assessed in the presence of added vitamin E, 
α-T3 was over 6 times more protective than α-TOH.  These effects may be dependent 
on the experimental conditions, as Yoshida et al found similar reactivities of α-TOH 
and α-T3 in liposomal membranes (8).   
Other functions of the tocotrienols have been described for which the 
tocopherols show less activity.  α-Tocotrienol was reported to be an effective inhibitor 
of cholesterol biosynthesis in vitro and in vivo by means of inhibition of HMG CoA 
reductase activity (9).  This inhibition was found to occur by means of post-
transcriptional regulation of enzyme levels (10).  Tocotrienols were also much more 
effective than tocopherols at inhibiting glutamate-induced neuronal cell death and 12-
lipoxygenase activity (11,12).  Additionally, while α-TOH appears to reduce 
endothelial expression of adhesion molecules, α-T3 has been found to be more potent 
(13).  These effects suggest an anti-atherogenic potential of the tocotrienols.  Other 
studies have implicated the tocotrienols in the prevention/treatment of cancer (14).  
Several studies have shown that tocotrienols cause the induction of apoptosis and 
inhibition of cell proliferation in cancer cells, whereas α-TOH does not (15,16).   
Tocotrienols are more rapidly taken up into cells than tocopherols, including 
being readily absorbed through the skin (11,17,18).  A greater membrane affinity is 
seen for the tocotrienols compared with the tocopherols in vitro in the rapid transfer of 
tocotrienols between membranes (11,17,18).  This effect is seen in vitro by the rapid 
transfer of tocotrienols between membranes (8).  The tocotrienols have been shown to  
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be more uniformly distributed throughout the lipid membrane bilayer and show a 
stronger disordering of membrane lipids (7).  Electron spin resonance studies have 
indicated that tocotrienols are located closer to the surface of liposomal lipid 
membrane bilayers than the tocopherols.  This same methodology was used to 
conclude that effects of tocopherols and tocotrienols on membrane fluidity, and 
molecular motion throughout the membrane are similar (6,8). Other lipid components 
of the membrane have been shown to affect the fluidity of the membrane, as well as 
the activity of membrane-associated enzymes.  Incorporation of cholesterol into 
microsomal membranes decreases both rotational and translational mobilities of the 
membranes.  This in turn affects the activities of membrane-bound enzymes (19), 
including that of cytochrome b5, a component of the cytochrome P450 
monooxygenase system (20).  Fluidizing effects are produced when isoamyl alcohols 
are incorporated into the membrane (21). 
The metabolism of tocopherols and tocotrienols to water-soluble metabolites 
followed by their excretion in the urine occurs via an initial ω-hydroxylation of the 
phytyl side-chain by the tocopherol-ω-hydroxylase enzyme, cytochrome P450 
CYP4F2 (22).  This process plays a key role in the regulation of vitamin E status due 
to the preferential metabolism of the non-α isomers of vitamin E.  This may be a 
means by which the organism is able to minimize the concentration of vitamers which 
potentially have the greatest deleterious effects.  Here we investigated the effects of 
tocopherols and tocotrienols on microsomal membranes and the activity of enzymes 
within these membranes, and demonstrate tocotrienols-specific effects on these 
parameters. 
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Materials and Methods 
Most chemicals were purchased from Sigma with the exception of the 
tocotrienols, which were a gift from Volker Berl (BASF, Ludvigshafen, Germany).  
Pyridine and N,O-bis-[Trimethylsilyl]-trifluoroacetamide containing 
1%Trimethylchrorosilane (BSTFA + 1%TMCS) were from Pierce Chemical Co., 
Rockford, IL.  Pooled human liver microsomes, purified cytochrome P450 reductase, 
and specific recombinant human cytochrome P450 enzymes expressed in insect cell 
microsomes with human cytochrome P450 reductase, and with or without recombinant 
human cytochrome B5, were purchased from BD Gentest (Woburn, MA).   
Microsome preparation   
Microsomal fractions from fresh rat liver were prepared by differential 
centrifugation as described previously (22) and resuspended in 100mM KH2PO4 
buffer, pH 7.4 and stored at -80
oC until use.  Microsomal protein content was 
determined using the Biorad protein kit (kit # 500-0002; Biorad, Hercules, CA). 
Microsomal metabolism 
Microsomal metabolism of vitamin E vitamers to their corresponding 13’OH 
or 13’COOH metabolites was carried out using 0.1 mg/ml rat or human liver 
microsomal protein, or 10-20 pmol/ml insect microsome-expressed P450.   
Microsomes were pre-incubated 0-60 min with substrate vitamers complexed with 1% 
bovine serum albumin (BSA fraction IV) which allowed for incorporation of the 
vitamer into the membrane.  A 0 - 30 min reaction was initiated with the addition of 
0.5 - 1.0 mM NADPH, with or without 0.5 - 1.0 mM NAD.  The reaction was 
terminated with the addition of 0.1 volume 3N HCl, and metabolites, substrate, and 
membrane cholesterol extracted with ice cold ethanol, methyl-tert-butyl-ether, and 
hexane in a 1: 0.5: 8 volume ratio.  Extracts were evaporated under N2 to dryness and 
derivatized in Pyridine using BSTFA + 1%TMCS.  Derivatized samples were  
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analyzed by gas chromatography-mass spectrometry (GC-MS) as described previously 
(22).  Unless noted, all microsomal activity is expressed as µmoles of metabolite per 
membrane cholesterol, as endogenous membrane cholesterol is a good internal 
standard for microsomal mass. 
Metabolism of other substrates was carried out in a similar manner to vitamin 
E with the following differences.  Testosterone, 7-ethoxycoumarin, and lauric acid 
were added to the reaction mixture in ethanol vehicle and the reaction was terminated 
by the addition of 4 volumes of ethyl acetate and products were extracted into this 
solvent.  p-Nitrophenol metabolism was terminated with the addition of 0.2 volumes 
of trichloroacetic acid and the protein was pelleted at 10,000 x g for 8 min.  The 
resulting supernatant was mixed with 0.5 volumes of 2N NaOH and p-nitrocatechol 
production was assessed by spectrophotometry (535 nm) using a 0 min incubation 
preparation as the blank.  Glucose-6-phosphate metabolism to glucose was measured 
using a modification of the glucose dehydrogenase coupled assay described by Alegre 
et al (23).  Briefly, 12.5 mM glucose-6-phosphate was incubated with 0.2 mg/ml rat 
liver microsome and 1.8 mM EDTA in KH2PO4 buffer for 1 hour at 37
oC.  The 
glucose dehydrogenase reaction was initiated by adding 12 IU/ml glucose 
dehydrogenase (Sigma) and 2 mM NAD for 15min at 37
oC.  Production of NADH 
was measured by spectrophotometry (340 nm) using a 0 min incubation preparation as 
the blank. 
Microsomal enzyme activity and inhibition 
Inhibition of activities of several microsomal enzymes by tocopherols and 
tocotrienols, or other membrane lipids, was assessed using activities of these enzymes 
toward model substrates of each enzyme as shown in Table 4.1 in combination with 
the test substances.  The test substance was pre-incubated with the microsomal 
membrane for 0 – 60 min in the presence or absence of NADPH.  The enzymatic  
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Table 4.1 
Reactions occurring in microsomal membranes and the enzymes carrying out each 
reaction. 
Substrate Metabolite  Enzyme  Reference 
Vitamin E 
(VitE) 
13’OH+13’COOH-VitE CYP4F  (22) 
Testosterone 
(TST) 
6β-OH-TST  CYP3A (24) 
Testosterone 
(TST) 
16α-OH-TST  CYP2C (25) 
7-Ethoxycoumarin 
(7-EC) 
7-Hydroxycoumarin 
(7-HC) 
CYP1A, 
CYP2B 
(26,27) 
Lauric Acid 
(LA) 
12-OH-LA CYP4A  (28) 
Lauric Acid 
(LA) 
11-OH-LA CYP4A  (29) 
p-nitrophenol 
(p-NP) 
p-nitrocatechol 
(p-NC) 
CYP2E (30) 
Glucose-6-
Phosphate 
Glucose Glucose-6-
Phosphatase 
(23) 
Cytochrome C  Reduced Cytochrome C  CYP Reductase  (31)  
 
 
122 
reaction was initiated by the addition of substrate plus additional NADPH.  In the case 
of glucose-6-phosphatase activity, the loaded microsomes were re-isolated after the 
pre-incubation by ultracentrifugation for 1 hour at 100,000 x g to remove remaining 
NADPH.    
Pyrene eximerization 
Lateral diffusivity of the microsomal membrane was assessed by pyrene 
eximerization.  1 mg/ml rat liver microsome was incubated for 1 hour with 6 µM 
pyrene (added in 10µl acetone) at 25
oC.  α-TOH (150 nmol per 0.1mg protein) or γ-T3 
(60 nmol per 0.1mg protein), as their BSA complex, plus 0.5 mM NADPH were then 
added, and the incubation continued for 1hr at 37
oC.  These were vitamin E 
concentrations which resulted in equivalent membrane vitamer concentrations.   
Microsomes were re-isolated by ultracentrifugation for 1 hr at 100,000 x g and 
resuspended at 1 mg/ml in KH2PO4 buffer.  Pyrene eximerization was measured by 
fluorometry with an exitation wavelength of 334 nm.  Monomer emission was 
measured at 391 nm and eximer emission at 470.  The fluorescence intensity of minus-
pyrene controls was subtracted from that of samples.  Efficiency of pyrene eximer 
formation was expressed as the ratio of fluorescence intensity of eximer (Ie) to 
monomer (Im).  
Diphenyl-hexatriene fluorescence anisotropy 
The rotational  mobility of the microsomal membrane was evaluated using 1,6-
diphenyl-1,3,5-hexatriene as a probe.  0.1 mg/ml rat liver microsome was incubated 
for 1 hour with 0.25 µM DPH (added in 10 µl dimethylformamide).  α-TOH or γ-T3 
loading and membrane re-isolation was done as for pyrene eximerization experiments.  
Fluorescence anisotropy was measured and expressed as rs values as described by 
Garda and Brenner (21).    
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Microsomal Cytochrome P450 reductase activity 
The reduction of exogenous cytochrome c was used to measure the effect of γ-
T3 on microsomal cytochrome P450 reductase activity.  0.2 mg/ml rat liver 
microsomes were pre-incubated with 75 nmol γ-T3 per mg protein and 1mM NADPH.  
Loaded microsomes were re-isolated by ultracentrifugation at 100,000 x g for 1 hour 
and resuspended (0.2 mg/ml protein) in 50 mM KH2PO4 containing 0.1 mM EDTA 
(pH 7.7).  Two mg cytochrome c was added and the reaction initiated with 0.8 mM 
NADPH.  Cytochrome P450 reductase activity was calculated by measuring the rate of 
change in absorption at 550 nm. 
NADPH reduction of Microsomal Cytochrome P450 and b5 
Reduction of microsomal cytochrome P450 was determined using a 
modification of the method of Omura and Sato (32).  0.25 mg/ml rat liver microsomes 
were incubated 1 hour with or without 1.5 µmol/mg protein α-TOH or 0.6 µmol/mg 
protein  γ-T3 (as their BSA complexes) and 0.5 mM NADPH at 37
oC.  The 
microsomes were re-isolated by centrifugation at 100,000 x g for 1 hr and resuspended 
in KH2PO4  buffer.  The microsomes were again treated for 5 min with 0.5 mM 
NADPH.  Samples were then bubbled with CO for 1 min and the absorbance from 
400-500 nm was measured and compared with controls to which no NADPH had been 
added during the pre-incubation.  Reduced cytochrome P450 was assessed by 
spectrophotometry at 450 nm and reduced cytochrome b5 at 426 nm.   
Microsomal depletion or enrichment of cholesterol 
Rat liver microsomes were depleted of cholesterol by incubating 2 mg/ml 
microsomes with 50% hydroxypropyl-β-cyclodextrin in KH2PO4 buffer for 1.5 hr at 
37
oC.   Rat liver microsomes were enriched in cholesterol by a 1 hr incubation of 0.8 
mg/ml microsome with cholesterol-loaded hydroxypropyl-β-cyclodextrin at 37
oC.  
Cholesterol depleted or enriched microsomes were isolated from buffer by  
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centrifugation at 100,000 x g for 1hr, and resuspended in KH2PO4 buffer.  Membrane 
cholesterol content was determined by GC-MS (22).  
Statistical Analysis 
  All statistical analysis was done using the statistical program included in the 
OriginLab Origin 7 graphing software.  Where applicable, data represent mean and 
standard deviation of duplicate or triplicate determinations.  Comparison of 
differences between treatments was done using a two-sample t-test.  Enzyme kinetics 
data were fit to the best curve using Origin 7 non-linear curve fit software. 
 
Results  
The metabolite production from added α-TOH,  γ-TOH and γ-T3 substrates 
was determined as a function of increasing tocopherol concentration in microsomes 
prepared from rat liver (Figure 4.1).  The metabolism of the tocopherols increased 
until plateauing at their respective Vmax values.  γ-T3 metabolism increased with 
substrate concentration through 60-70 µM, after which metabolite production is 
increasingly inhibited.  The same result was obtained for α- and δ-T3 and to a lesser 
extent with δ-TOH and with the non-methylated substrate tocol (data not shown).  It 
was possible that this was due to substrate inhibition of the tocopherol-ω-hydroxylase 
enzyme which metabolizes vitamin E (22).  However, the vitamers which exhibited 
this substrate inhibition were also those having the greatest affinity for the lipid 
membrane, as determined by the differences in efficiency of membrane association 
when the vitamers were added to the microsomal suspensions (data not shown).   
A second possible explanation for the observed inhibition was substrate-
induced alteration of the membrane environment, which may have affected 
membrane-associated enzyme activity.  To test this hypothesis, we measured the 
activity of several microsomal enzymes which do not metabolize vitamin E, after  
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Figure 4.1 
Kinetics of metabolism of α-TOH, γ-TOH and γ-T3 on 100 µg/ml rat liver microsome 
demonstrating self-inhibition of metabolism by γ-T3.  Increasing concentrations of 
vitamer-BSA complex were pre-incubated 60 min with microsomes.  Reaction was 
initiated by the addition of 0.5 mM NADPH.  Data points represent sum of 13’OH and 
13’COOH metabolites (µmoles per µmoles membrane cholesterol).   Curves were fit 
using Origin 7 FFT curve smoothing function. 
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loading the microsomes with α-TOH or γ-T3 to equal extents.  The metabolism by rat 
liver microsomes of model substrates to their known metabolites was used as a 
measure of activity of the microsomal enzymes which carry out these reactions as 
shown in Table 4.1. The microsomes were pre-loaded with the vitamers at 
concentrations determined to yield equivalent membrane vitamer concentrations 
during the reaction.  The results shown in Figure 4.2A indicate α-TOH, at 0.6 
µmol/mg protein in the membrane (150 µM in reaction) did not affect the metabolism 
of any enzyme tested.  γ-T3 at this same membrane concentration (60 µM in reaction 
medium) strongly inhibited the metabolism of testosterone (TST) to its CYP3A 
metabolite, 6β-OH-TST, and moderately inhibited its metabolism to the CYP2C 
metabolite, 16α-OH-TST.  Similar effects were seen in the metabolism of lauric acid 
to the 11-OH and 12-OH metabolites, respectively, suggesting the effect of γ-T3 was 
not by modifying substrate access to the enzyme.  Glucose-6-phosphatase activity was 
not inhibited by γ-T3, indicating the effect may be specific to P450 enzymes.  Figure 
4.2B illustrates that the effect of γ-T3 concentration on enzyme activity is more 
pronounced for some microsomal P450 enzymes (e.g. CYP3A) than others (e.g. 
CYP2C).   
A P450 inhibitor may often alter the activity of P450 enzymes by competitive 
inhibition.  The kinetics of testosterone metabolism in the absence or presence of γ-T3 
was used to determine the mechanism of inhibition of the tocotrienol.  The kinetic 
curves in Figure 4.3 for 6β-OH-TST and 16α-OH-TST synthesis were fit to the 
Michaelis-Menten equation and demonstrated a decrease in Vmax in the presence of 
60 µM γ-T3 for both CYP3A and CYP2C-mediated testosterone metabolism.  There 
was no significant effect on Km, indicating γ-T3 acted as a non-competitive inhibitor 
of these enzymes.    
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Figure 4.2 
Effects of α-TOH and γ-T3 on microsomal membrane-associated enzymes.  (A) 
Reactions were carried with in 0.1 mg/ml rat liver microsomal membranes loaded 60 
min with α-TOH or  γ-T3 in the presence of 0.5 mM NADPH as described in 
Materials and Methods.  200 µM testosterone (TST), 200 µM lauric acid (LA), 100 
µM 7-ethoxycoumarin (7-EC), and 500 µM p-nitrophenol were added to individual 
samples at time 60 min along with 0.5 mM NADPH and incubated 20-30 min.   
Glucose-6-phosphatase assay was carried out as described in Materials and Methods.  
(B) Reactions were carried out for testosterone as in (A) but with increasing 
concentrations of γ-T3 during the pre-incubation on either 0.1 mg/ml rat liver 
microsome or 4 pmol CYP3A4 microsome.  Results are presented as percentage of 
control where control = 100%.  Data points represent mean +/- std dev.  Statistical 
differences from controls: * = p<0.005, # = p<0.05 
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Figure 4.3 
Kinetics of testosterone metabolism by rat liver microsomes in the presence or 
absence of γ-T3 (60 nmol/100 µg protein (60µM)).  100 µg/ml microsome was pre-
incubated 60 min in the presence or absence of  γ-T3 and 0.5 mM NADPH.  A 20 min 
reaction was initiated by the addition of testosterone and 0.5 mM NADPH.  A) 
CYP3A mediated 6β-OH-TST production.  B) CYP2C-mediated 16α-OH-TST 
production.  Product formation is expressed relative to microsomal cholesterol 
content.  Vmax and Km values were derived by a hyperbolic fit to the Michaelis-
Menten equation using Origin 7 software. 
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There is a significant body of evidence suggesting the membrane lipid 
environment may affect the interaction and activity of membrane-bound multi-enzyme 
systems such as the cytochrome P450 reductase/cytochrome b5/cytochrome P450 
electron transfer complex (19-21).  Increases in membrane unsaturated fatty acids 
increases the molecular mobility of the membrane, enhancing electron transfer 
between membrane redox proteins such as cytochrome b5 reductase and cytochrome 
b5 (21,33).  On the other hand, decreases in membrane fluidity (i.e. increased 
ordering), which occurs when membrane cholesterol content is increased, has the 
opposite effect, i.e. inhibition of cytochrome b5 reduction and NADH-cytochrome c 
reductase (19,20).  We assessed rotational and lateral mobility of rat liver microsomal 
membranes in the presence of α-TOH or γ-T3 by diphenyl-hexatriene (DPH) 
fluorescence anisotropy and pyrene eximerization, respectively.  The results (Table 
4.2)  revealed that both α-TOH and γ-T3 decreased the lateral mobility of the 
microsomal membrane (decreased pyrene eximer formation) with α-TOH displaying 
the greater ordering effect.  However, γ-T3 also decreased the rotational mobility in 
the membrane (increased anisotropy) while α-TOH showed no significant effect on 
this parameter relative to vehicle control.  γ-T3 thus appears to act in a manner similar 
to that of cholesterol, which decreases both the lateral and rotational mobility of 
membranes (19).  The effect of membrane cholesterol concentration on cytochrome 
P450 activity was examined using testosterone metabolism as a marker for activity 
(Figure 4.4A).  A four fold increase in cholesterol content dramatically reduced 
CYP3A activity (6β-OH-TST formation) and to a lesser extent, CYP2C activity (16α-
OH-TST formation), similar to the effect produced by γ-T3.  A five-fold decrease in 
membrane cholesterol concentration resulted in a more moderate effect on testosterone 
metabolism, and this treatment had similar effects on the two enzyme activities.  
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Table 4.2  
Effects of α-TOH and γ-T3 on rotational and lateral mobility of rat liver microsomal 
membranes as determined by 1,6-diphenyl-1,3,5-hexatriene (DPH) fluorescence 
anisotropy and pyrene eximerization, respectively, as described in Materials and 
Methods.  α-TOH and γ-T3 were incubated with rat liver microsome plus 1 mM 
NADPH at a concentration of 1.5 and 0.6 nmol/mg protein, respectively.  * indicates 
significantly different from control (p<0.05). 
 
 
    Fluorescence Anisotropy 
(rs) 
Pyrene Eximerization 
(Ie/Im) 
Control  0.298 (0.013)  0.242 (0.029) 
α-TOH  0.322 (0.024)  0.061 (0.016)* 
γ-T3  0.348 (0.024)*  0.118 (0.023)*  
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Figure 4.4 
(A)  Inhibition of testosterone metabolism by enrichment or removal of cholesterol 
from rat liver microsomes.  Cholesterol was loaded or removed from rat liver 
microsome as described in Materials and Methods.  100 µg/ml microsome was pre-
incubated 60 min in the presence or absence of γ-T3 and 0.5 mM NADPH.  A 20 min 
reaction was initiated in the resuspended microsomes by the addition of 200 µM 
testosterone and 0.5 mM NADPH.  (B)  Inhibition of testosterone (TST) metabolism 
by unsaturated fatty acids in rat liver microsomes.  100 µg/ml microsome was pre-
incubated 60 min in the presence or absence of γ-T3 or fatty acid and 0.5 mM 
NADPH.  Lipid not incorporated into the membrane was removed from supernatant by 
ultracentrifugation.   A 30 min reaction was initiated in the re-isolated microsomes by 
the addition of 200 µM testosterone and 0.5 mM NADPH.  Results are presented as 
percentage of control where control equals 100% enzyme activity.  Statistical 
differences from controls: * = p<0.05, # = p<0.1 
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The auto-inhibitory effect of γ-T3 on its own metabolism has also been 
observed in the ω-hydroxylation of fatty acids such as arachidonic acid, which is also 
catalyzed by the CYP4 family of P450 enzymes (34,35).  The results in Figure 4.4B 
illustrate an inhibitory effect of the unsaturated fatty acids arachidonic acid, oleic acid, 
and linoleic acid on testosterone metabolism, while their saturated counterparts had no 
effect.  This result correlates well with the observed P450 inhibition by the unsaturated 
tocotrienols but lack of effect of their saturated counterparts, the tocopherols.   
Additionally, the comparative degree to which CYP3A-mediated metabolism was 
inhibited compared with that of CYP2C was similar between γ-T3 and the unsaturated 
fatty acids, i.e. their effects being greater on CYP3A activity. 
The activity of the individual enzyme components of the rat liver microsomal 
P450 electron transfer complex was examined in the presence or absence of γ-T3.  
There was no effect of γ-T3 on the reduction of cytochrome C by cytochrome P450 
reductase (Figure 4.5A).  Testosterone metabolism was also evaluated, with or 
without the addition of 5-10 µg/ml purified human cytochrome P450 reductase.  The 
addition of exogenous reductase did not alter the inhibitory effects of γ-T3 on P450 
activity (data not shown).  The effects of γ-T3 on cytochrome b5 was analyzed using 
microsomes from insect cells expressing recombinant cytochrome P450 reductase, 
cytochrome P450 enzymes, and with or without recombinant cytochrome b5 (Figure 
4.5B).  In the case of both CYP3A4 and CYP2B6, the presence of cytochrome b5 
increased the activity of the P450 enzyme.  γ-T3 showed more of an inhibitory effect 
on substrate metabolism in the presence of b5 than in its absence, further suggesting 
the tocotrienols may be inhibiting membrane P450 activity by disrupting the electron 
flux between the electron transfer protein partners. 
The effects of α-TOH and γ-T3 on the reduction of the microsomal 
cytochrome b5 and cytochrome P450 was assessed using spectrophotometric analysis  
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Figure 4.5 
Effect of γ-T3 on microsomal cytochrome B5 and cytochrome P450 reductase activity.  
(A) 10 pmol insect microsomes expressing recombinant human CYP3A4 or CYP2B6, 
P450 reductase, and with or without cytochrome b5 were tested for inhibition of 
activity by γ-T3 using 200 µM testosterone (TST) or 7-ethoxycoumarin (7-EC) as 
substrates.  Reactions were carried out as described in Materials and Methods, with a 
60 min pre-inc containing microsome, with or without γ-T3, and 0.5 mM NADPH, 
and a 20 min incubation initiated by the addition of substrate plus 0.5 mM NADPH.  
(B) 0.1 mg/ml rat liver microsome was pre-incubated for 60 min with or without γ-T3 
plus 0.5 mM NADPH.  The resulting P450 reductase activity was measured as 
described in Materials and Methods.  Data represent means +/- std dev.  
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of the two heme proteins.  Reduced cytochrome b5 exhibits an absorbance peak at 426 
nm only when b5 is in its reduced state, and is not affected by the presence of CO 
(32).  Microsomal cytochrome P450 will not bind CO in its oxidized form, however 
upon reduction by the electron transport partners, P450 will bind CO, producing an 
absorbance peak at 450 nm.  Rat liver microsomes loaded for an hour with 1.5 µmol 
α-TOH or 0.6 µmol γ-T3/mg protein, in the presence or absence of NADPH during 
the loading, were assessed for their level of reduced b5 and P450 compared with 
controls.  The results in Figure 4.6 illustrate the presence of the vitamers in the 
membrane did not affect the reduction of either cytochrome b5 or P450.  Additionally, 
the presence of NADPH during the pre-incubation, which amplified the inhibitory 
effects of the tocotrienols, did not affect the reduction of either protein. 
 
Discussion 
Tocotrienols have attracted increasing attention in recent years due to their 
potential anti-atherogenic and anti-cancer effects.  These unsaturated vitamers of 
vitamin E exhibit activities that their saturated tocopherol counterparts do not.   
However, plasma concentrations of the tocotrienols are usually far below that of α-
TOH, due largely to their rapid catabolism and elimination via the tocopherol-ω-
oxidation pathway.  Here we report an inhibitory activity of the tocotrienols on certain 
microsomal enzymes that is not exhibited by the tocopherols when compared at 
similar membrane concentrations.  Certain enzymes were more sensitive to the 
presence of tocotrienols than others.  The inhibition was non-competitive, eliminating 
the possibility that the tocotrienols simply compete for binding sites on the P450 
enzymes.  The inhibition was greater when the microsomal reaction system was pre-
incubated in the presence of NADPH, suggesting a mechanism involving a tocotrienol  
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Figure 4.6 
α-TOH and γ-T3 do not effect the reduction of cytochrome P450 or cytochrome b5 in 
rat liver microsomal membranes.  Microsomes were loaded with 1.5 µmol α-TOH/mg 
protein or 0.6 µmol  γ-T3/mg protein in the presence or absence of NADPH as 
described in Materials and Methods.  A 5 min reaction was then carried out with 
loaded microsomes in the presence of 0.5 mM NADPH.  Reduction of cytochromes 
P450 and b5 were measured by spectrophotometer after bubbling samples with CO for 
1 min.  All absorbances were read against blanks lacking NADPH.  No significant 
differences were found between the controls and experimental samples. 
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metabolite.  However, tocotrienol inhibition was also seen in microsomes expressing 
only P450 enzymes which are not involved in vitamin E metabolism.   
We investigated a mechanism involving disruption by the tocotrienols of the 
transfer of electrons from NADPH to the cytochrome P450 resulting from alteration of 
membrane physical properties.  Several studies have reported effects of membrane 
lipid composition on the electron transport chain (19-21).  Lipids which decrease the 
fluidity of the membrane are postulated to affect the diffusion rate of the individual 
protein components of the electron transfer system, thereby limiting the interaction 
between these components (36-38).  Such is the case for cholesterol, which decreases 
both lateral and rotational fluidity of the membrane (19).  On the other hand 
unsaturated fatty acids, which increase the fluidity of the microsomal membrane, also 
inhibit the activity of P450s, an effect which has been proposed to be due to the 
detergent effects of the fatty acids on the electron transfer components within the 
membrane (34).  Here we demonstrated that both cholesterol and unsaturated fatty 
acids inhibit P450 activity while the analogous saturated fatty acids had no effect.  
Additionally, these lipids inhibited CYP3A more strongly than CYP2C, a pattern 
identical to that of tocotrienol-mediated inhibition.   
Both tocopherols and tocotrienols behave like cholesterol in that they 
decreased the lateral diffusivity of the microsomal membrane, in agreement with the 
electron spin resonance results of Yoshida et al (8).  However, γ-T3, but not α-TOH, 
decreased the rotational mobility of the membrane, as does cholesterol.  The 
unsaturation of the phytyl tail of the tocotrienols is clearly important to its inhibitory 
activity.  Fatty acid inhibition of P450 activity is analogous, in that only the 
unsaturated fatty acids are inhibitory.  The conformation that the unsaturated carbon 
tail assumes in the lipid bilayer may be the driving force of these inhibitory effects.    
 
 
137 
Structure-activity differences of tocopherols and tocotrienols on membrane 
enzyme activity may also arise due to the depth at which the vitamer resides in the 
membrane bilayer.  Suzuki et al suggested that α-T3 sits closer to the membrane 
surface than α-TOH, based on small differences in ordering of the liquid crystalline 
state at carbons 10-13 of phospholipid fatty acid chains (6).  On the other hand, 
Yoshida et al reported similar locations in the membrane based on similar electron 
spin resonance parameters, using similar spin labels (8).  Grau and Ortiz found 
evidence in lipid vesicles that the α-, γ-, β-, and δ-TOHs are found at various depths 
within the membrane (39).  These differences may potentially affect the function of 
membrane proteins according to their depth in the lipid bilayer.   
The precise nature of the interactions between the electron transfer partners in 
the microsomal cytochrome P450 complex are not yet fully understood.  In the 
simplest model, cytochrome P450 reductase accepts two electrons from NADPH, and 
transfers these electrons one at a time to cytochrome P450, without the need for 
cytochrome b5 (40,41).  The cytochrome P450 then uses these reducing equivalents 
for the oxidation reactions specific to the individual P450.  However, the transfer of 
the second electron is rate limiting (42).  Several mechanisms have been proposed in 
which cytochrome b5 facilitates the input of the second electron into the P450 
enzyme, thereby increasing the rate of the P450 reaction.  These include (a) directly 
increasing the rate of input of the second electron, (b) enhancement of coupling of 
NADPH oxidation to substrate oxidation, (c) by forming a two electron acceptor 
complex with the P450, or (d) as an effector of the P450 enzyme, as reviewed by 
Schenkman and Jansson (43).  In all cases there is postulated a direct interaction 
between the P450 reductase, the P450 enzyme, and the cytochrome b5 protein.  There 
are several reports on the random distribution of the electron transfer components 
throughout the membrane (38,44,45).  The rates of electron transfer and substrate  
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oxidation are therefore dependent on how these components move through and 
associate within the membrane.  We demonstrated that γ-T3 in the membrane did not 
affect reduction of cytochrome C by P450 reductase.  Since cytochrome C was added 
exogenously, the fluidity of the membrane would not affect its access to the 
membrane-bound reductase.  Addition of exogenous P450 reductase has no protective 
effect against γ-T3 mediated P450 inhibition.  Since the additional reductase is not 
associated with the membrane, it may not be able to complex with the P450 enzyme in 
such a way as to rescue it from the effects of γ-T3.   
Cytochrome b5 does not play an obligate role in all CYP450 reactions (43).  
However, for many P450 reactions such as 3A4 mediated testosterone hydroxylation 
and CYP2E1 mediated 7-ethoxycoumarin de-ethylation, enhancement of activity by 
b5 is so great that it is considered an obligate partner (46-48).  Disruption of 
interaction between b5 and the P450 enzymes would then be expected to have varied 
effects on activity measurements, dependent on both the type of P450 and the 
substrate in question (49). Such a P450 dependent effect was observed in the 
inhibition of P450 activity by γ-T3.  A greater dependence of CYP3A4 on cytochrome 
b5 compared to other P450 enzymes may explain the greater effect of the presence of 
b5 on CYP3A4 inhibition compared with CYP2B6 (Figure 4.5B).  No effect was 
observed for membrane tocotrienols on reduction of the cytochrome P450 or b5 in rat 
liver microsomes.  This may be largely due to the presence of many different 
endogenous P450s in the rat microsomal membrane, many of which are not sensitive 
to the interaction with cytochrome b5.  However, the possibility still exists that the 
tocotrienols are interacting directly with the P450 enzyme to inhibit its activity, in a 
site that is distinct from the catalytic site, resulting in the observed non-competitive 
inhibition.  
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The inhibitory effects described here of the tocotrienols on microsomal 
enzymes suggests a physiological role of the tocopherol-ω-hydroxylase pathway in the 
minimization of membrane tocotrienols concentration.  The CYP4F2 enzyme 
responsible for this activity shows a large preference for the tocotrienols over their 
tocopherol counterparts (Sontag and Parker, unpublished results).  This may be a 
mechanism by which cell membranes are protected from the adverse effects of 
membrane tocotrienols.  Cytochrome P450 enzymes are involved in the elimination of 
a variety of toxic xenobiotics, as well as in the metabolism of numerous endogenous 
compounds (50).  Alteration of the activity of these enzymes can dramatically alter 
physiological functions.  The tocotrienols have been reported to cause growth 
inhibition and apoptotic cell death in a variety of cell types (16,51-54), but the 
mechanism has not been elucidated.  The membrane effects of tocotrienols reported 
here may be relevant to these phenomena.  The tocotrienols may mimic several of the 
membrane effects of free cholesterol, as shown here for membrane fluidity.  Work by 
Feng et al showed that the endoplasmic reticulum is the site of cholesterol-induced 
cytotoxicity in macrophages (55).  Free cholesterol disrupts the membrane to a degree 
that generates a chain of responses, ultimately leading to apoptosis.  Cells therefore 
tightly regulate the free cholesterol content of the ER relative to other membranes 
(56).  Membrane effects of tocotrienols may generate a similar response, ultimately 
leading to the apoptotic cell death reported for these vitamers.   
In summary, we describe an inhibitory effect of tocotrienols, but not 
tocopherols, on the activity of several cytochrome P450 enzymes found in the 
microsomal membrane.  The inhibition is not generalized, but rather occurs toward the 
cytochrome P450 enzymes and takes place by a non-competitive mechanism.  Both 
the α-TOH and γ-T3 decrease the lateral fluidity of the membrane, while only γ-T3 
decreases the rotational fluidity in a manner similar to that of free cholesterol.  Other  
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evidence presented here implicates a change in membrane environment induced by 
tocotrienols that in turn alter the interactions of the electron transfer partners involved 
in P450 activity.  All together, the data presented here provide a further indication of 
the importance of the tocopherol-ω-hydroxylase mediated mechanisms that mammals 
have developed to retain α-TOH, while eliminating others, especially the tocotrienols, 
that may cause detrimental effects.  While the mechanisms behind the observed 
vitamer-specific effects on membrane function have not been fully elucidated, they 
clearly merit further investigation.  
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Chapter V 
Overall Conclusions 
 
The main objective of this dissertation was to characterize the metabolic 
pathway by which the structural vitamers of vitamin E are metabolized to water 
soluble compounds for elimination in the urine.  The presence of these metabolites in 
the urine has been known for half a century, although the mechanism(s) behind this 
transformation were unknown.  Based on structural differences between vitamin and 
CEHC metabolite, it was speculated that these changes came about by means of an ω-
hydroxylation of the terminal carbon of the phytyl tail of the vitamin, followed by 
sequential β-oxidation similar to that observed for fatty acids.  
  The experiments described here confirm the proposed ω-hydroxylation/β-
oxidation pathway of vitamin E metabolism.  All forms of vitamin E are metabolized 
through this pathway.  Studies using individually expressed microsomal cytochrome 
P450 enzymes reveal the initial enzyme in this pathway is the membrane-bound 
tocopherol-ω-hydroxylase CYP4F2.  This enzyme is highly substrate specific, 
demonstrating greater activity for certain forms of vitamin E based on minor 
variations in vitamer structure.  This structural selectivity plays a major role in the 
high plasma levels of α-TOH and relatively low levels of the other vitamers. The α-
tocopherol binding protein (α-TTP) appears to function together with tocopherol-ω-
hydroxylase to promote the retention of α-TOH and the elimination of the other 
vitamer forms.  Inhibition of this pathway changes plasma vitamin E status by 
decreasing the catabolism of the non-α- vitamers, allowing their plasma and tissue 
concentrations to increase.  The work reported here has been followed up in vivo by 
Ikeda et al, in which the in vivo inhibition of this enzyme with sesame lignans inhibits 
the urinary excretion of the CEHC vitamin E metabolites (1).   
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The kinetics of metabolism of the vitamers is similar between human liver 
microsomes containing all hepatic P450 enzymes and microsomes containing only 
CYP4F2.  Also, other CYP4F isoforms which have a high degree of sequence 
homology show little or no catabolic activity toward any of the vitamers.  Taken 
together these results suggest CYP4F2 is the major human liver ω-hydroxylase of 
vitamin E.   
CYP4F2 is also found in other tissues including the lungs, kidneys, and testes.  
The metabolism of vitamin E in these specific tissues may indicate the importance of 
maintaining low levels of non-α vitamers in certain cell types above others.  On the 
other hand, given the natriuretic and anti-inflammatory nature of the most abundant 
metabolite,  γ-CEHC, these tissues may express CYP4F2 as a means of local 
generation of an important physiological factor. 
Kinetic analyses also revealed the allosteric nature of the tocopherol-ω-
hydroxylase with its substrates.  This cooperativity allows for low levels of 
metabolism when vitamin concentration around the enzyme is low, but a high rate of 
metabolism with increasing concentrations of the non-α forms of the vitamin.   
Additionally this cooperativity provides a mechanism by which α-TOH acts as a 
positive effector of metabolism of the other vitamers, increasing their rates of 
catabolism.  This explains the phenomenon observed during supplementation with α-
TOH, where α-TOH causes a decrease in the plasma levels of the other tocopherols, 
and an increase in their urinary excretion.  By this mechanism, the other vitamers are 
available for physiological function when α-TOH concentration is limiting, but may 
be eliminated when α-TOH levels are such that the other forms are not necessary.   
The rate of catabolism of the tocotrienols is greater than that of the 
tocopherols.  The tocotrienols have been previously shown to be cytotoxic at 
concentrations at which the tocopherols show no deleterious effects.  Here the  
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tocotrienols are shown to have effects on mobility of membrane constituents and on 
the activity of the P450 enzymes found in the membrane of the endoplasmic 
reticulum, acting to decrease membrane fluidity, and inhibit the activity of P450 
enzymes.  These effects are not observed for the tocopherols.  The evidence presented 
here points toward an effect of the tocotrienols on the interactions of the electron 
transfer partners of the P450 enzyme complex, especially cytochrome b5.  Some P450 
enzymes are more sensitive to these effects than others, which is consistent with P450 
enzymes varying in the degree to which they are dependent on interactions with 
cytochrome b5.  The effects of the tocotrienols on the ER membrane may provide an 
explanation for their cytotoxicity.  This additionally provides a motivation for the 
tocopherol-ω-hydroxylase enzyme to have developed a high affinity for molecules 
with the structural features of the tocotrienols, in order to minimize the membrane 
concentrations of these vitamers. 
The full significance of the tocopherol-ω-hydroxylase pathway of vitamin E 
metabolism is still largely unknown.  The generation of tocopherol-ω-hydroxylase 
knockout mice is a logical next step in understanding the relevance of this enzyme to 
physiological functions.  These mice should allow for the achievement of plasma and 
tissue levels of the non-α vitamers that rival those of α-TOH, if this enzyme is truly 
the major source of selective elimination of these vitamers.  Additionally, the interplay 
of tocopherol-ω-hydroxylase and the α-tocopherol transfer protein (α-TTP) will be 
better understood through various crosses of these mice with the previously generated 
TTP-null mouse.  The potential anti-atherogenic and anti-carcinomic effects of the 
tocopherols and tocotrienols may be accentuated by an increase of the plasma levels of 
these vitamers, making inhibition of tocopherol-ω-hydroxylase a possible target of 
therapeutic approaches.  This will of course require an understanding of the balance of 
positive outcomes of increased vitamer plasma and tissue concentrations with the toxic  
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effects which may result from increased concentrations of the tocotrienols in the 
membrane.  Commonly used drugs such as the anti-fungal ketoconazole affect 
Vitamin E status through the inhibition of tocopherol-ω-hydroxylase (1).  Likewise, 
hepatic diseases such as hepatitis may compromise the activity of the tocopherol-ω-
hydroxylase enzyme, factors which must be considered in the use of drugs which 
affect cytochrome P450 activity, and the effects of disease states on vitamin E status.  
Finally, while the ω-hydroxylation enzyme involved in the metabolism of 
vitamin E has been characterized, the remaining enzymes responsible for β-oxidation 
of the hydroxylated metabolite have not been determined.  Unpublished results from 
our lab indicate a variety of cell types which do not metabolize vitamin E are able to 
carry out the subsequent phytyl tail truncation when presented with intermediates from 
this pathway.  The enzymes involved in this β-oxidation may thus be found in a 
variety of tissues and may be involved in metabolizing any circulating intermediates 
generated by CYP4F2-expressing tissues.     
Intracellularly, the tocopherol-ω-hydroxylase enzyme is resident in the 
endoplasmic reticulum.  The β-oxidation enzymes may reside in other organelles, as is 
the case for the metabolism of LTB4, whose metabolism originates in the ER but 
whose subsequent metabolism is carried out in the peroxisomes (2).  If this is the case, 
the lipophilic intermediary metabolites require a means of reaching these other 
organelles, be it by non-specific transfer between membranes, or by means of specific 
transfer proteins yet to be discovered. 
  Overall, the discovery of the enzyme responsible for the selective elimination 
of vitamin E opens many new doors for understanding the reasons the α-TOH form of 
this vitamin is so favored in animals throughout nature.  This will hopefully lead to 
new insights in the role of this vitamin in physiological function and disease 
prevention.  
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